<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40640989</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1468-3148</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of applied research in intellectual disabilities : JARID</Title><ISOAbbreviation>J Appl Res Intellect Disabil</ISOAbbreviation></Journal><ArticleTitle>Exploring Barriers to Mammography Access for Women With Intellectual Disabilities: A Meta-Synthesis of the Perspectives of Four Stakeholder Groups.</ArticleTitle><Pagination><StartPage>e70095</StartPage><MedlinePgn>e70095</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jar.70095</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Breast cancer is as frequent in women with intellectual disabilities as the general population, but the mammography uptake rate for women with intellectual disabilities is almost a third lower. This meta-synthesis aimed to explore physical and psychosocial barriers to mammography access for women with intellectual disabilities from the perspectives of the women themselves, healthcare professionals, paid carers and family members.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A systematic search of six databases yielded 12 papers for thematic synthesis review.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three analytic themes were developed: (i) knowing what to expect; (ii) knowing who will assume responsibility and (iii) making adjustments.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mammography screening elicits anxiety from both women with intellectual disabilities and their supporters (whether paid, family or healthcare professional). A formulation-based approach to mammography attendance may help to provide tailored information to women with intellectual disabilities, whilst easing the pressures placed upon their support network and healthcare professionals.</AbstractText><CopyrightInformation>&#xa9; 2025 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pitt</LastName><ForeName>Adam</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9114-9983</Identifier><AffiliationInfo><Affiliation>Learning Disability Partnership, Huntingdon, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodge</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0416-8188</Identifier><AffiliationInfo><Affiliation>Division of Health Research, Health Innovation One, Lancaster University, Lancaster, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Appl Res Intellect Disabil</MedlineTA><NlmUniqueID>9613616</NlmUniqueID><ISSNLinking>1360-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008607" MajorTopicYN="Y">Intellectual Disability</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008327" MajorTopicYN="Y">Mammography</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="Y">Health Services Accessibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073597" MajorTopicYN="N">Stakeholder Participation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="Y">Patient Acceptance of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">breast cancer</Keyword><Keyword MajorTopicYN="N">healthcare access</Keyword><Keyword MajorTopicYN="N">inequalities</Keyword><Keyword MajorTopicYN="N">intellectual disabilities</Keyword><Keyword MajorTopicYN="N">mammography</Keyword><Keyword MajorTopicYN="N">qualitative</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>23</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40640989</ArticleId><ArticleId IdType="doi">10.1111/jar.70095</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Arana&#x2010;Chicas, E., A. Kioumarsi, A. Carroll&#x2010;Scott, P. M. Massey, A. C. Klassen, and M. Yudell. 2020. &#x201c;Barriers and Facilitators to Mammography Among Women With Intellectual Disabilities: A Qualitative Approach.&#x201d; Disability &amp; Society 35, no. 8: 1290&#x2013;1314.</Citation></Reference><Reference><Citation>Barnett&#x2010;Page, E., and J. Thomas. 2009. &#x201c;Methods for the Synthesis of Qualitative Research: A Critical Review.&#x201d; BMC Medical Research Methodology 9: 1&#x2013;11.</Citation></Reference><Reference><Citation>Benzies, K. M., S. Premji, K. A. Hayden, and K. Serrett. 2006. &#x201c;State&#x2010;of&#x2010;the&#x2010;Evidence Reviews: Advantages and Challenges of Including Grey Literature.&#x201d; Worldviews on Evidence&#x2010;Based Nursing 3, no. 2: 55&#x2013;61.</Citation></Reference><Reference><Citation>Bigby, C., M. Whiteside, and J. Douglas. 2019. &#x201c;Providing Support for Decision Making to Adults With Intellectual Disability: Perspectives of Family Members and Workers in Disability Support Services.&#x201d; Journal of Intellectual &amp; Developmental Disability 44, no. 4: 396&#x2013;409.</Citation></Reference><Reference><Citation>Bradbury&#x2010;Jones, C., J. Rattray, M. Jones, and S. MacGillivray. 2013. &#x201c;Promoting the Health, Safety and Welfare of Adults With Learning Disabilities in Acute Care Settings: A Structured Literature Review.&#x201d; Journal of Clinical Nursing 22, no. 11&#x2013;12: 1497&#x2013;1509.</Citation></Reference><Reference><Citation>British Medical Association. 2019. Best Interests Decision&#x2010;Making for Adults Who Lack Capacity. BMA. https://www.bma.org.uk/media/1850/bma&#x2010;best&#x2010;interests&#x2010;toolkit&#x2010;2019.pdf.</Citation></Reference><Reference><Citation>Byrnes, K., S. Hamilton, G. J. McGeechan, C. O'Malley, J. Mankelow, and E. L. Giles. 2020. &#x201c;Attitudes and Perceptions of People With a Learning Disability, Family Carers, and Paid Care Workers Towards Cancer Screening Programmes in the United Kingdom: A Qualitative Systematic Review and Meta&#x2010;Aggregation.&#x201d; Psycho&#x2010;Oncology 29, no. 3: 475&#x2013;484.</Citation></Reference><Reference><Citation>Chad&#x2010;Friedman, E., S. Coleman, L. N. Traeger, et&#xa0;al. 2017. &#x201c;Psychological Distress Associated With Cancer Screening: A Systematic Review.&#x201d; Cancer 123, no. 20: 3882&#x2013;3894. https://doi.org/10.1002/cncr.30904.</Citation></Reference><Reference><Citation>Chan, D. N., B. M. Law, D. W. Au, W. K. So, and N. Fan. 2022. &#x201c;A Systematic Review of the Barriers and Facilitators Influencing the Cancer Screening Behaviour Among People With Intellectual Disabilities.&#x201d; Cancer Epidemiology 76: 102084.</Citation></Reference><Reference><Citation>Collins, K., A. McClimens, S. Mekonnen, and L. Wyld. 2014. &#x201c;Breast Cancer Information and Support Needs for Women With Intellectual Disabilities: A Scoping Study.&#x201d; Psycho&#x2010;Oncology 23, no. 8: 892&#x2013;897. https://doi.org/10.1002/pon.3500.</Citation></Reference><Reference><Citation>Consedine, N. S., C. Magai, Y. S. Krivoshekova, L. Ryzewicz, and A. I. Neugut. 2004. &#x201c;Fear, Anxiety, Worry, and Breast Cancer Screening Behavior: A Critical Review.&#x201d; Cancer Epidemiology and Prevention Biomarkers 13, no. 4: 501&#x2013;510.</Citation></Reference><Reference><Citation>Cooke, A., D. Smith, and A. Booth. 2012. &#x201c;Beyond PICO: The SPIDER Tool for Qualitative Evidence Synthesis.&#x201d; Qualitative Health Research 22, no. 10: 1435&#x2013;1443. https://doi.org/10.1177/1049732312452938.</Citation></Reference><Reference><Citation>Critical Appraisal Skills Programme. 2013. &#x201c;Qualitative Research Checklist: 10 Questions to Help You Make Sense of Qualitative Research.&#x201d; https://casp&#x2010;uk.net/wp&#x2010;content/uploads/2018/01/CASP&#x2010;Qualitative&#x2010;Checklist&#x2010;2018.pdf.</Citation></Reference><Reference><Citation>Disability Rights Commission. 2006. Equal Treatment: Closing the Gap. A Formal Investigation Into Physical Health Inequalities Experienced by People With Learning Disabilities and/or Mental Health Problems. DRC. http://disability&#x2010;studies.leeds.ac.uk/files/library/DRC&#x2010;Health&#x2010;FI&#x2010;main.pdf.</Citation></Reference><Reference><Citation>Doherty, A. J., H. Atherton, P. Boland, et&#xa0;al. 2020. &#x201c;Barriers and Facilitators to Primary Health Care for People With Intellectual Disabilities and/or Autism: An Integrative Review.&#x201d; BJGP Open 4, no. 3: bjgpopen20X101030.</Citation></Reference><Reference><Citation>Dunn, M., I. Strnadov&#xe1;, J. L. Scully, et&#xa0;al. 2024. &#x201c;Equitable and Accessible Informed Healthcare Consent Process for People With Intellectual Disability: A Systematic Literature Review.&#x201d; BMJ Quality and Safety 33, no. 5: 328&#x2013;339.</Citation></Reference><Reference><Citation>Emerson, E. 2021. &#x201c;Inequalities and Inequities in the Health of People With Intellectual Disabilities.&#x201d; In Oxford Research Encyclopedia of Global Public Health. Oxford University Press.</Citation></Reference><Reference><Citation>Equality Act. 2010. &#x201c;Equality Act 2010 (C.15).&#x201d; https://www.legislation.gov.uk/ukpga/2010/15/contents.</Citation></Reference><Reference><Citation>Francis, R. 2013. Report of the Mid Staffordshire NHS Foundation Trust Public Inquiry: Executive Summary (Vol. 947). Stationery Office. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/279124/0947.pdf.</Citation></Reference><Reference><Citation>Goldsmith, L., H. Skirton, and C. Webb. 2008. &#x201c;Informed Consent to Healthcare Interventions in People With Learning Disabilities&#x2014;An Integrative Review.&#x201d; Journal of Advanced Nursing 64, no. 6: 549&#x2013;563.</Citation></Reference><Reference><Citation>Greenwood, N. W., D. Dreyfus, and J. Wilkinson. 2014. &#x201c;More Than Just a Mammogram: Breast Cancer Screening Perspectives of Relatives of Women With Intellectual Disability.&#x201d; Intellectual and Developmental Disabilities 52, no. 6: 444&#x2013;455. https://doi.org/10.1352/1934&#x2010;9556&#x2010;52.6.444.</Citation></Reference><Reference><Citation>Hanna, L. M., L. Taggart, and W. Cousins. 2011. &#x201c;Cancer Prevention and Health Promotion for People With Intellectual Disabilities: An Exploratory Study of Staff Knowledge.&#x201d; Journal of Intellectual Disability Research 55, no. 3: 281&#x2013;291.</Citation></Reference><Reference><Citation>Jenuwine, E. S., and J. A. Floyd. 2004. &#x201c;Comparison of Medical Subject Headings and Text&#x2010;Word Searches in MEDLINE to Retrieve Studies on Sleep in Healthy Individuals.&#x201d; Journal of the Medical Library Association 92, no. 3: 349&#x2013;353.</Citation></Reference><Reference><Citation>Kirby, S., and J. Hegarty. 2010. &#x201c;Breast Awareness Within an Intellectual Disability Setting.&#x201d; European Journal of Oncology Nursing 14, no. 4: 328&#x2013;336.</Citation></Reference><Reference><Citation>Ko, J., and P. Sammons. 2013. Effective Teaching: A Review of Research and Evidence. CfBT Education Trust.</Citation></Reference><Reference><Citation>Lord, A. J., S. Field, and I. C. Smith. 2017. &#x201c;The Experiences of Staff Who Support People With Intellectual Disability on Issues About Death, Dying and Bereavement: A Metasynthesis.&#x201d; Journal of Applied Research in Intellectual Disabilities 30, no. 6: 1007&#x2013;1021. https://doi.org/10.1111/jar.12376.</Citation></Reference><Reference><Citation>MacMillan Cancer Support. n.d. &#x201c;Impact Briefs: Psychological and Emotional Support.&#x201d; https://www.macmillan.org.uk/_images/Psychological&#x2010;and&#x2010;Emotional&#x2010;Support_tcm9&#x2010;283186.pdf.</Citation></Reference><Reference><Citation>McIlfatrick, S., L. Taggart, and M. Truesdale&#x2010;Kennedy. 2011. &#x201c;Supporting Women With Intellectual Disabilities to Access Breast Cancer Screening: A Healthcare Professional Perspective.&#x201d; European Journal of Cancer Care 20, no. 3: 412&#x2013;420. https://doi.org/10.1111/j.1365&#x2010;2354.2010.01221.x.</Citation></Reference><Reference><Citation>Mencap. 2012. Death by Indifference: 74 Deaths and Counting. A Progress Report 5&#x2009;Years on. MenCap. https://www.mencap.org.uk/sites/default/files/2016&#x2010;08/DeathbyIndifference&#x2010;74deathsandcounting.pdf.</Citation></Reference><Reference><Citation>Mental Capacity Act. 2005. &#x201c;Mental Capacity Act 2005 (C.9).&#x201d; https://www.legislation.gov.uk/ukpga/2005/9/contents.</Citation></Reference><Reference><Citation>Michael, J., and A. Richardson. 2008. &#x201c;Healthcare for All: The Independent Inquiry Into Access to Healthcare for People With Learning Disabilities.&#x201d; Tizard Learning Disability Review 13, no. 4: 28&#x2013;34. https://doi.org/10.1108/13595474200800036.</Citation></Reference><Reference><Citation>Moher, D., A. Liberati, J. Tetzlaff, and D. G. Altman. 2009. &#x201c;Preferred Reporting Items for Systematic Reviews and Meta&#x2010;Analyses: The PRISMA Statement.&#x201d; Annals of Internal Medicine 151, no. 4: 264&#x2013;269. https://doi.org/10.7326/0003&#x2010;4819&#x2010;151&#x2010;4&#x2010;200908180&#x2010;00135.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. 2017a. Advanced Breast Cancer: Diagnosis and Treatment. NICE. https://www.nice.org.uk/guidance/cg81/chapter/Recommendations#providing&#x2010;information&#x2010;and&#x2010;support&#x2010;for&#x2010;decision&#x2010;making.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. 2017b. Learning Disabilities: Identifying and Managing Mental Health Problems. NICE. https://www.nice.org.uk/guidance/qs142.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. 2018a. Care and Support of People Growing Older With Learning Disabilities. NICE. https://www.nice.org.uk/guidance/ng96/chapter/Recommendations#overarching&#x2010;principles.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. 2018b. Decision&#x2010;Making and Mental Capacity. NICE. https://www.nice.org.uk/guidance/ng108/chapter/Recommendations#best&#x2010;interests&#x2010;decision&#x2010;making.</Citation></Reference><Reference><Citation>NHS England Digital. 2021. Health and Care of People With Learning Disabilities Experimental Statistics. NHS England Digital. https://digital.nhs.uk/data&#x2010;and&#x2010;information/publications/statistical/health&#x2010;and&#x2010;care&#x2010;of&#x2010;people&#x2010;with&#x2010;learning&#x2010;disabilities/experimental&#x2010;statistics&#x2010;2020&#x2010;to&#x2010;2021/breast&#x2010;cancer&#x2010;screening.</Citation></Reference><Reference><Citation>NHS England Digital. 2024. Breast Screening Programme, England, 2022&#x2013;23. NHS England Digital. https://digital.nhs.uk/data&#x2010;and&#x2010;information/publications/statistical/breast&#x2010;screening&#x2010;programme/england&#x2010;&#x2010;&#x2010;2022&#x2010;23/mainreport2223#section&#x2010;4&#x2010;uptake&#x2010;of&#x2010;invitations.</Citation></Reference><Reference><Citation>Nystrom, L., N. Bjurstam, H. Jonsson, S. Zackrisson, and J. Frisell. 2017. &#x201c;Reduced Breast Cancer Mortality After 20+ Years of Follow&#x2010;Up in the Swedish Randomized Controlled Mammography Trials in Malm&#xf6;, Stockholm, and G&#xf6;teborg.&#x201d; Journal of Medical Screening 24, no. 1: 34&#x2013;42. https://doi.org/10.1177/0969141316648987.</Citation></Reference><Reference><Citation>Office for Health Improvement &amp; Disparities. 2021. Breast Screening Pathway Requirements Specification. NHS England. https://www.gov.uk/government/publications/breast&#x2010;screening&#x2010;pathway&#x2010;requirements&#x2010;specification/breast&#x2010;screening&#x2010;pathway&#x2010;requirements&#x2010;specification#end&#x2010;to&#x2010;end&#x2010;pathway.</Citation></Reference><Reference><Citation>Parliamentary and Health Service Ombudsman. 2009. Six Lives: The Provision of Public Services to People With Learning Disabilities. Stationery Office. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/250750/0203.pdf.</Citation></Reference><Reference><Citation>Patja, K., P. Eero, and M. Iivanainen. 2001. &#x201c;Cancer Incidence Among People With Intellectual Disability.&#x201d; Journal of Intellectual Disability Research 45, no. 4: 300&#x2013;307.</Citation></Reference><Reference><Citation>Polit, D., and C. Beck. 2006. Essentials of Nursing Research: Methods, Appraisal and Utilization. 6th ed. Lippincott Williams and Wilkins.</Citation></Reference><Reference><Citation>Purtzer, M. A., and L. Overstreet. 2014. &#x201c;Transformative Learning Theory: Facilitating Mammography Screening in Rural Women.&#x201d; Oncology Nursing Forum 41, no. 2: 176&#x2013;184. https://doi.org/10.1188/14.ONF.176&#x2010;184.</Citation></Reference><Reference><Citation>Ramsey, L., A. Albutt, K. Perfetto, et&#xa0;al. 2022. &#x201c;Systemic Safety Inequities for People With Learning Disabilities: A Qualitative Integrative Analysis of the Experiences of English Health and Social Care for People With Learning Disabilities, Their Families and Carers.&#x201d; International Journal for Equity in Health 21, no. 1: 13.</Citation></Reference><Reference><Citation>Royal College of Psychiatrists. 2014. Care Pathways for People With Intellectual Disability. RCP. https://www.rcpsych.ac.uk/docs/default&#x2010;source/members/faculties/intellectual&#x2010;disability/id&#x2010;fr&#x2010;id&#x2010;05.pdf?sfvrsn=11e73693_4.</Citation></Reference><Reference><Citation>Shady, K., S. Phillips, and S. Newman. 2024. &#x201c;Barriers and Facilitators to Healthcare Access in Adults With Intellectual and Developmental Disorders and Communication Difficulties: An Integrative Review.&#x201d; Review Journal of Autism and Developmental Disorders 11, no. 1: 39&#x2013;51.</Citation></Reference><Reference><Citation>Smith, M., B. Manduchi, &#xc9;. Burke, R. Carroll, P. McCallion, and M. McCarron. 2020. &#x201c;Communication Difficulties in Adults With Intellectual Disability: Results From a National Cross&#x2010;Sectional Study.&#x201d; Research in Developmental Disabilities 97: 103557.</Citation></Reference><Reference><Citation>Sullivan, S. G., E. J. Glasson, R. Hussain, et&#xa0;al. 2003. &#x201c;Breast Cancer and the Uptake of Mammography Screening Services by Women With Intellectual Disabilities.&#x201d; Preventive Medicine 37, no. 5: 507&#x2013;512. https://doi.org/10.1016/S0091&#x2010;7435(03)00177&#x2010;4.</Citation></Reference><Reference><Citation>Sullivan, S. G., L. M. Slack&#x2010;Smith, and R. Hussain. 2004. &#x201c;Understanding the Use of Breast Cancer Screening Services by Women With Intellectual Disabilities.&#x201d; Sozial&#x2010; und Pr&#xe4;ventivmedizin 49, no. 6: 398&#x2013;405. https://doi.org/10.1007/s00038&#x2010;004&#x2010;3121&#x2010;z.</Citation></Reference><Reference><Citation>Swaine, J. G., S. Dababnah, S. L. Parish, and K. Luken. 2013. &#x201c;Family Caregivers' Perspectives on Barriers and Facilitators of Cervical and Breast Cancer Screening for Women With Intellectual Disability.&#x201d; Intellectual and Developmental Disabilities 51, no. 1: 62&#x2013;73. https://doi.org/10.1352/1934&#x2010;9556&#x2010;51.01.062.</Citation></Reference><Reference><Citation>Taggart, L., M. Truesdale&#x2010;Kennedy, and S. McIlfatrick. 2011. &#x201c;The Role of Community Nurses and Residential Staff in Supporting Women With Intellectual Disability to Access Breast Screening Services.&#x201d; Journal of Intellectual Disability Research 55, no. 1: 41&#x2013;52. https://doi.org/10.1111/j.1365&#x2010;2788.2010.01345.x.</Citation></Reference><Reference><Citation>Taua, C., C. Neville, and J. Hepworth. 2014. &#x201c;Research Participation by People With Intellectual Disability and Mental Health Issues: An Examination of the Processes of Consent.&#x201d; International Journal of Mental Health Nursing 23, no. 6: 513&#x2013;524.</Citation></Reference><Reference><Citation>Thomas, J., and A. Harden. 2008. &#x201c;Methods for the Thematic Synthesis of Qualitative Research in Systematic Reviews.&#x201d; BMC Medical Research Methodology 8, no. 1: 45. https://doi.org/10.1186/1471&#x2010;2288&#x2010;8&#x2010;45.</Citation></Reference><Reference><Citation>Truesdale&#x2010;Kennedy, M., L. Taggart, and S. McIlfatrick. 2011. &#x201c;Breast Cancer Knowledge Among Women With Intellectual Disabilities and Their Experiences of Receiving Breast Mammography.&#x201d; Journal of Advanced Nursing 67, no. 6: 1294&#x2013;1304. https://doi.org/10.1111/j.1365&#x2010;2648.2010.05595.x.</Citation></Reference><Reference><Citation>Walsh, D., and S. Downe. 2005. &#x201c;Meta&#x2010;Synthesis Method for Qualitative Research: A Literature Review.&#x201d; Journal of Advanced Nursing 50, no. 2: 204&#x2013;211. https://doi.org/10.1111/j.1365&#x2010;2648.2005.03380.x.</Citation></Reference><Reference><Citation>Walsh, M. E., R. Galvin, C. Loughnane, C. Macey, and N. F. Horgan. 2015. &#x201c;Factors Associated With Community Reintegration in the First Year After Stroke: A Qualitative Meta&#x2010;Synthesis.&#x201d; Disability and Rehabilitation 37, no. 18: 1599&#x2013;1608. https://doi.org/10.3109/09638288.2014.974834.</Citation></Reference><Reference><Citation>Walsh, S., J. Hegarty, E. Lehane, et&#xa0;al. 2022. &#x201c;Determining the Need for a Breast Cancer Awareness Educational Intervention for Women With Mild/Moderate Levels of Intellectual Disability: A Qualitative Descriptive Study.&#x201d; European Journal of Cancer Care 31, no. 4: e13590.</Citation></Reference><Reference><Citation>Walsh, S., M. O'Mahony, J. Hegarty, et&#xa0;al. 2022. &#x201c;Defining Breast Cancer Awareness and Identifying Barriers to Breast Cancer Awareness for Women With an Intellectual Disability: A Review of the Literature.&#x201d; Journal of Intellectual Disabilities 26, no. 2: 491&#x2013;508.</Citation></Reference><Reference><Citation>Weedon&#x2010;Fekj&#xe6;r, H., P. R. Romundstad, and L. J. Vatten. 2014. &#x201c;Modern Mammography Screening and Breast Cancer Mortality: Population Study.&#x201d; British Medical Journal: 348&#x2013;356. https://doi.org/10.1136/bmj.g3701.</Citation></Reference><Reference><Citation>Weise, J., R. Cvejic, and J. Trollor. 2024. &#x201c;Strategies for Accessible Breast Screening for People With Intellectual Disability.&#x201d; Journal of Primary Care &amp; Community Health 15: 1&#x2013;9.</Citation></Reference><Reference><Citation>White, A., R. Sheehan, J. Ding, et&#xa0;al. 2023. Learning From Lives and Deaths: People With a Learning Disability and Autistic People (LeDeR) Report for 2022. LeDeR Autism and Learning Disability Partnership. King's College London. https://www.kcl.ac.uk/ioppn/assets/fans&#x2010;dept/leder&#x2010;2022&#x2010;v2.0.pdf.</Citation></Reference><Reference><Citation>Whittle, E. L., K. R. Fisher, S. Reppermund, R. Lenroot, and J. Trollor. 2018. &#x201c;Barriers and Enablers to Accessing Mental Health Services for People With Intellectual Disability: A Scoping Review.&#x201d; Journal of Mental Health Research in Intellectual Disabilities 11, no. 1: 69&#x2013;102.</Citation></Reference><Reference><Citation>Wilkinson, J. E., C. E. Deis, D. J. Bowen, and B. G. Bokhour. 2011. &#x201c;&#x2018;It's Easier Said Than Done&#x2019;: Perspectives on Mammography From Women With Intellectual Disabilities.&#x201d; Annals of Family Medicine 9, no. 2: 142&#x2013;147. https://doi.org/10.1370/afm.1231.</Citation></Reference><Reference><Citation>Willis, D. S. 2016. &#x201c;What Influences Women With Intellectual Disabilities to Attend Breast Screening? Experiences of Women Who Have and Have Not Participated.&#x201d; British Journal of Learning Disabilities 44, no. 4: 269&#x2013;276. https://doi.org/10.1111/bld.12158.</Citation></Reference><Reference><Citation>Willis, D. S., C. M. Kennedy, and L. Kilbride. 2008. &#x201c;Breast Cancer Screening in Women With Learning Disabilities: Current Knowledge and Considerations.&#x201d; British Journal of Learning Disabilities 36, no. 3: 171&#x2013;184. https://doi.org/10.1111/j.1468&#x2010;3156.2008.00520.x.</Citation></Reference><Reference><Citation>Willis, D. S., L. Kilbride, D. Horsburgh, and C. M. Kennedy. 2015. &#x201c;Paid&#x2010; and Family&#x2010;Carers' Views on Supporting Women With Intellectual Disability Through Breast Screening.&#x201d; European Journal of Cancer Care 24, no. 4: 473&#x2013;482. https://doi.org/10.1111/ecc.12245.</Citation></Reference><Reference><Citation>Wood, S., S. Gangadharan, F. Tyrer, et&#xa0;al. 2014. &#x201c;Successes and Challenges in the Implementation of Care Pathways in an Intellectual Disability Service: Health Professionals' Experiences.&#x201d; Journal of Policy and Practice in Intellectual Disabilities 11, no. 1: 1&#x2013;7.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40640988</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-4804</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of medicinal chemistry</Title><ISOAbbreviation>J Med Chem</ISOAbbreviation></Journal><ArticleTitle>Discovery of a Novel EGFR PROTAC Degrader against C797S Resistance Mutation with Potent Antitumor Efficacy in NSCLC Treatment.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jmedchem.5c00693</ELocationID><Abstract><AbstractText>C797S mutation is the predominant resistance mechanism for the third-generation EGFR inhibitor osimertinib in nonsmall cell lung cancer (NSCLC). To overcome this drug resistance, a novel class of EGFR<sup>C797S</sup> PROTAC degraders was developed in human NSCLC models. <b>9ea</b> was identified as the lead compound, demonstrating potent degradation of EGFR<sup>C797S</sup> and other main EGFR mutants (DC<sub>50</sub> = 2.9 &#xb1; 1.1 nM, <i>D</i><sub>max</sub> = 93.1 &#xb1; 6.5%). It exhibited good selectivity for degradation over EGFR<sup>WT</sup>. Additionally, <b>9ea</b> induced cell cycle arrest and apoptosis. Mechanistic studies revealed that <b>9ea</b> selectively induced EGFR<sup>C797S</sup> degradation through a VHL and proteasome-dependent manner and downregulated EGFR-associated transcriptome. In NSCLC (EGFR<sup>C797S</sup>) xenograft mouse models, <b>9ea</b> significantly inhibited tumor growth (74.7% TGI @ 50 mg/kg) and effectively depleted EGFR proteins in tumor tissue. These findings suggest that <b>9ea</b> is a potent and selective EGFR<sup>C797S</sup> PROTAC degrader with potential for the treatment of EGFR mutant-driven NSCLC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoxue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Yakun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piao</LastName><ForeName>Yongjun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2530-410X</Identifier><AffiliationInfo><Affiliation>School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shuang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-8099-3203</Identifier><AffiliationInfo><Affiliation>School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Chem</MedlineTA><NlmUniqueID>9716531</NlmUniqueID><ISSNLinking>0022-2623</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>23</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40640988</ArticleId><ArticleId IdType="doi">10.1021/acs.jmedchem.5c00693</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40640971</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-7283</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>BMC psychology</Title><ISOAbbreviation>BMC Psychol</ISOAbbreviation></Journal><ArticleTitle>Suicidal behaviours among adults living with cancer in Ghana: prevalence and associated risk factors.</ArticleTitle><Pagination><StartPage>769</StartPage><MedlinePgn>769</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40359-025-03122-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Globally, cancer is a complex disease that, if not detected and treated early, can lead to death. The diagnosis of cancer typically causes a profound crisis in the lives of those affected, leading to psychological challenges. People living with cancer tend to exhibit suicidal behaviours due to the difficult nature of the disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The primary aim of this study was to determine the prevalence and factors influencing Suicidal behaviours among adults living with cancer at Korle Bu Teaching Hospital, Ghana.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A convenience sampling method was employed to collect data from cancer patients at Korle Bu Teaching Hospital. Data were gathered using structured questionnaires and the Columbia-Suicide Severity Rating Scale (C-SSRS). Descriptive and inferential statistics, including frequency tables, percentages, and regression analysis with Stata 17, were used for data analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study found that 57.2% of participants reported suicidal ideation, 14.1% had attempted suicide, and 11.3% had planned suicide. Age, sex, educational level, income, occupational status, and marital status were significantly associated with suicidal behaviour (p-value&#x2009;&lt;&#x2009;0.001). Multivariate logistic regression results shows that patients who experienced recent significant life changes were 15 times more likely to experience suicidal ideation (AOR: 15.0, 95% CI: 9.1-22.9, p&#x2009;&lt;&#x2009;0.001), twice as likely to have a suicidal plan (AOR: 2.0, 95% CI: 1.0-3.1, p&#x2009;=&#x2009;0.001), and over five times more likely to attempt suicide (AOR: 5.41, 95% CI: 2.22-6.07, p&#x2009;&lt;&#x2009;0.001) compared to those who did not experience significant life changes. In Addition, patients who believed they were a burden to others were over three times more likely to experience suicidal ideation (AOR: 3.3, 95% CI: 1.15-4.59, p&#x2009;&lt;&#x2009;0.001), five times more likely to have a suicidal plan (AOR: 5.0, 95% CI: 3.07-8.13, p&#x2009;&lt;&#x2009;0.001), and three times more likely to attempt suicide (AOR: 3.0, 95% CI: 2.1-5.3, p&#x2009;&lt;&#x2009;0.001) compared to those who did not feel this way.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study reveals a high prevalence of suicidal behaviours among cancer patients, with many reporting suicidal ideation, attempts, and plans. Socio-demographic factors, including age, sex, educational level, income, occupational status, and marital status, were linked to higher suicide risk. To achieve SDG 3, particularly Target 3.4 (promoting mental health and well-being) and Target 3.8 (ensuring universal health coverage), the Ghana Health Service and the Ministry of Health should integrate mental health support into routine cancer care.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abu Bonsra</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0002-8463-1397</Identifier><AffiliationInfo><Affiliation>Department of Population and Behavioural Sciences, Fred N. Binka School of Public Health, University of Health and Allied Sciences, Hohoe, Ghana. emmanuelabubonsra14@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Justice</LastName><ForeName>Boateng</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Fred N. Binka School of Public Health, University of Health and Allied Sciences, Hohoe, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ananga</LastName><ForeName>Mark Kwame</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Population and Behavioural Sciences, Fred N. Binka School of Public Health, University of Health and Allied Sciences, Hohoe, Ghana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychol</MedlineTA><NlmUniqueID>101627676</NlmUniqueID><ISSNLinking>2050-7283</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059020" MajorTopicYN="Y">Suicidal Ideation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="Y">Suicide, Attempted</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Ghana</Keyword><Keyword MajorTopicYN="N">Mental health</Keyword><Keyword MajorTopicYN="N">Suicidal behaviours</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Ethical approval for the study was obtained from the University of Health and Allied Sciences Review Ethics Committee (UHAS-REC A.30 [111]22&#x2013;23) and the Institutional Review Board of the Korle Bu Teaching Hospital&#x2019;s Research Department. Informed consent was obtained from all participants after they were fully briefed about the study&#x2019;s purpose, procedures, risks, and potential benefits. Given the sensitive nature of the topic, the study acknowledged the potential risk of triggering mental health issues, such as distress or emotional discomfort, during data collection. To address these risks, the following measures were implemented: participants were informed of their right to withdraw from the study at any point without consequence; they were provided with a list of mental health support services, including counsellors and helplines, should they feel distressed; trained research assistants were available to provide immediate support or assistance if needed; and any participant showing signs of distress was immediately offered a referral for counselling. Confidentiality was ensured through the use of pseudonyms, and all data was securely stored in an encrypted, password-protected database, with access limited to the Principal Investigator and the research supervisor. The study adhered to strict ethical guidelines to protect the rights and well-being of all participants. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>23</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40640971</ArticleId><ArticleId IdType="doi">10.1186/s40359-025-03122-z</ArticleId><ArticleId IdType="pii">10.1186/s40359-025-03122-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Cancer [Internet]. 2025 [cited 2025 Jan 6]. Available from: https://www.who.int/health-topics/cancer#tab=tab_1</Citation></Reference><Reference><Citation>Calati R, Fang F, Mostofsky E, Shen Q, Di Mattei VE, Garcia-Foncillas J, Baca-Garcia E, Cipriani A, Courtet P. Cancer and suicidal ideation and behaviours: protocol for a systematic review and meta-analysis. BMJ Open. 2018;8(8):e020463.</Citation><ArticleIdList><ArticleId IdType="pubmed">30099389</ArticleId><ArticleId IdType="pmc">6089268</ArticleId></ArticleIdList></Reference><Reference><Citation>Araya T, Gidey W. Factors associated with suicidal ideation and attempt among Cancer patients in ayder comprehensive specialized hospital: cross-sectional, mekelle, Ethiopia. Open Public Health J. 2020;13(1).</Citation></Reference><Reference><Citation>Molla A, Aderaw M, Mulat H, Fanta B, Nenko G, Adane A. Suicidal ideation, attempt, and associated factors among people living with cancer in ethiopia: a cross-sectional study. Ann Gen Psychiatry. 2022;21(1):28.</Citation><ArticleIdList><ArticleId IdType="pubmed">35883094</ArticleId><ArticleId IdType="pmc">9316727</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization, Mental Health ATLAS. 2020. Geneva: WHO; 2020. Available from: https://www.who.int/publications/i/item/9789240036703</Citation></Reference><Reference><Citation>Lovero KL, Dos Santos PF, Come AX, Wainberg ML, Oquendo MA. Suicide in global mental health. Curr Psychiatry Rep. 2023;25(6):255&#x2013;62. Available from: https://doi.org/10.1007/s11920-023-01423-x</Citation></Reference><Reference><Citation>Joshi P, Song HB, Lee SA. Association of chronic disease prevalence and quality of life with suicide-related ideation and suicide attempt among Korean adults. Indian J Psychiatry. 2017;59(3):352&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29085096</ArticleId><ArticleId IdType="pmc">5659087</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenhals S, Mali ME, Sutherland EK, Sorenson J, Dedey F, Nellermoe J, Flores-Huidobro Martinez A, Tounkara MD, Price RR, Brownson KE. Geospatial availability of breast cancer treatment modalities and hypothetical access improvement in ghana: A nationwide survey. PLoS ONE. 2023;18(9):e0291454.</Citation><ArticleIdList><ArticleId IdType="pubmed">37713441</ArticleId><ArticleId IdType="pmc">10503733</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira MADN, Silva EPD, Sampaio AN, Mallagoli ISS, Barbosa DA, Domingos TDS, Belasco AGS. Sociodemographic factors associated with suicidal behavior at a federal public university in the Western Brazilian Amazon. Rev Bras Enferm. 2023;76(Suppl 2):e20230102. https://doi.org/10.1590/0034-7167-2023-0102 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0034-7167-2023-0102</ArticleId><ArticleId IdType="pmc">10704696</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland DC, Walsh L, Napolitano S, Morita J, Jaiswal R. Suicide in patients with cancer: identifying the risk factors. Oncol (08909091). 2019;33(6).</Citation></Reference><Reference><Citation>Smith HR. Depression in cancer patients: Pathogenesis, implications and treatment (Review). Oncol Lett. 2015;9(4):1509&#x2013;14. Available from: https://doi.org/10.3892/ol.2015.2944</Citation></Reference><Reference><Citation>Sforzini L, Nettis MA, Mondelli V, Pariante CM. Inflammation in cancer and depression: a starring role for the kynurenine pathway. Psychopharmacology. 2019;236:2997&#x2013;3011.</Citation><ArticleIdList><ArticleId IdType="pubmed">30806743</ArticleId><ArticleId IdType="pmc">6820591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ossei PP, Niako N, Ayibor WG, Asante E, Safo FK, Safowaa A. Profile of suicide within the Northern part of ghana: A decade under review. South Afr J Psychiatry. 2022;28:1620.</Citation></Reference><Reference><Citation>International Agency for Research on Cancer. Ghana fact sheet [Internet]. Lyon: IARC. 2020 [cited 2025 Jan 6]. Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/288-ghana-fact-sheet.pdf</Citation></Reference><Reference><Citation>Cancer Screening in Five Continents (CanScreen5.). Country Fact Sheet: Ghana [Internet]. Lyon, France: International Agency for Research on Cancer (IARC); c2025 [cited 2025 Jan 06]. Available from: https://canscreen5.iarc.fr/?page=countryfactsheet&amp;q=GHA</Citation></Reference><Reference><Citation>Calys-Tagoe BN, Yarney J, Kenu E, et al. Profile of cancer patients seen at Korle Bu teaching hospital in Ghana (A cancer registry review). BMC Res Notes. 2014;7:577. https://doi.org/10.1186/1756-0500-7-577 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-0500-7-577</ArticleId><ArticleId IdType="pubmed">25164384</ArticleId><ArticleId IdType="pmc">4155104</ArticleId></ArticleIdList></Reference><Reference><Citation>Nebraska Youth Suicide Prevention. Suicide Behaviors Questionnaire-Revised [Internet]. 2019 [cited 2025 Jan 6]. Available from: https://youthsuicideprevention.nebraska.edu/wp-content/uploads/2019/09/SBQ-R.pdf</Citation></Reference><Reference><Citation>University of Washington. Columbia-Suicide Severity Rating Scale (C-SSRS) [Internet]. 2021 [cited 2025 Jan 6]. Available from: https://pcl.psychiatry.uw.edu/wp-content/uploads/2021/12/C-SSRS.pdf</Citation></Reference><Reference><Citation>Kolva E, Hoffecker L, Cox-Martin E. Suicidal ideation in patients with cancer: A systematic review of prevalence, risk factors, intervention, and assessment. Palliat Support Care. 2020;18(2):206&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">31554521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaorsky NG, Zhang Y, Tuanquin L, Bluethmann SM, Park HS, Chinchilli VM. Suicide among cancer patients. Nat Commun. 2019;10(1):207.</Citation><ArticleIdList><ArticleId IdType="pubmed">30643135</ArticleId><ArticleId IdType="pmc">6331593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghose B, Wang R, Tang S, Yaya S. Engagement in physical activity, suicidal thoughts and suicide attempts among older people in five developing countries. PeerJ. 2019;7:e7108.</Citation><ArticleIdList><ArticleId IdType="pubmed">31223536</ArticleId><ArticleId IdType="pmc">6570999</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallagoli ISS, Barbosa DA, Domingos TDS, Belasco AGS. Sociodemographic factors associated with suicidal behavior at a federal public university in the Western Brazilian Amazon. Revista Brasileira De Enfermagem 76Suppl. 2023;2(Suppl 2e20230102. https://doi.org/10.1590/0034-7167-2023-0102 .</Citation></Reference><Reference><Citation>Ganesh Kudva K, Abdin E, Vaingankar JA, Chua BY, Shafie S, Verma SK, Fung DSS, Mok Kwee H, Chong D, S. A., Subramaniam M. The relationship between suicidality and Socio-Demographic variables, physical disorders, and psychiatric disorders: results from the Singapore mental health study 2016. Int J Environ Res Public Health. 2021;18(8):4365. https://doi.org/10.3390/ijerph18084365 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph18084365</ArticleId><ArticleId IdType="pubmed">33924079</ArticleId><ArticleId IdType="pmc">8074258</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SA, Chung SH, Lee Y. Factors associated with suicide risk in advanced cancer patients: a cross-sectional study. Asian Pac J Cancer Prev. 2016;17(11):4831&#x2013;6. https://doi.org/10.22034/APJCP.2016.17.11.4831 .</Citation><ArticleIdList><ArticleId IdType="doi">10.22034/APJCP.2016.17.11.4831</ArticleId><ArticleId IdType="pubmed">28030907</ArticleId><ArticleId IdType="pmc">5454682</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobman B, Mansur A, Babalola D, Srinivasan AP, Antonio JM, Lu CY. Suicide among cancer patients: current knowledge and directions for observational research. J Clin Med. 2023;12(20):6563.</Citation><ArticleIdList><ArticleId IdType="pubmed">37892700</ArticleId><ArticleId IdType="pmc">10607431</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugawara A, Kunieda E. Suicide in patients with gastric cancer: a population-based study. Jpn J Clin Oncol. 2016;46(9):850&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">27307574</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Z, Jiang P, Zhang P, et al. Incidence, trend, and risk factors associated with suicide among patients with malignant intracranial tumors: a surveillance, epidemiology, and results analysis. Int J Clin Oncol. 2022;27(9):1386&#x2013;93. https://doi.org/10.1007/s10147-022-02206-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10147-022-02206-9</ArticleId><ArticleId IdType="pubmed">35781641</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Montoya J, Palacios-Espinosa X, Gracia-Ruiz J. Association between religion and suicidal behaviors in cancer patients. Revista Colombiana De Psiquiatria. 2017;46(4):209&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">29122227</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40640964</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-3305</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Parasites &amp; vectors</Title><ISOAbbreviation>Parasit Vectors</ISOAbbreviation></Journal><ArticleTitle>Clonorchis sinensis infection remodels chromatin accessibility in hepatocellular carcinoma.</ArticleTitle><Pagination><StartPage>276</StartPage><MedlinePgn>276</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13071-025-06909-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hepatocellular carcinoma (HCC) is a major global health concern, accounting for a significant proportion of liver cancer cases and related deaths. Clonorchis sinensis (C. sinensis) infection, a recognized carcinogen, has been implicated in the progression of liver diseases, including HCC. However, the precise epigenetic mechanisms underlying C. sinensis-associated HCC remain to be elucidated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To investigate the role of chromatin accessibility in C. sinensis-related HCC progression, we performed an assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) and RNA sequencing (RNA-seq) analyses of C. sinensis-infected (C. sinensis<sup>+</sup>) and non-C. sinensis-infected (C. sinensis<sup>-</sup>) HCC tumors. Integrated analyses were conducted to assess chromatin accessibility, transcription factor (TF) motifs, and histone modifications using ATAC-seq, RNA-seq, and classical chromatin immunoprecipitation-sequencing (ChIP-seq) datasets. A scratch wound assay was used to evaluate the effects of C. sinensis excretory/secretory products (CsESPs) on HCC cell migration.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">&#xa0;ATAC-seq analysis revealed 9,396 differentially accessible regions (DARs) in C. sinensis<sup>+</sup> HCC tumors compared with C. sinensis<sup>-</sup> HCC tumors. Additionally, several crucial TFs enriched in DARs were identified, including HNF4A, FOXO1, ELF4, and RELA. Combined&#xa0;ATAC-seq and RNA-seq analyses further&#xa0;revealed differentially expressed genes (DEGs) associated with metabolism, immune regulation, and cytoskeletal dynamics. Chromatin accessibility was closely associated with histone modifications such as H3K9ac, H3K4me2, H3K4me3, H3K27ac, H3K4me1, and CTCF binding. Notably, C. sinensis infection significantly increased the migratory capacity of HCC cells, as confirmed by molecular assays and clinical observations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study demonstrates that C. sinensis infection remodels chromatin accessibility and may contribute to HCC progression. Our work offers valuable insights into the pathogenesis of HCC in the context of parasitic infection and lays the groundwork for future biomarker and therapeutic target discovery.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Weilong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Caibiao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Junxian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Qiumei</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Yuling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Taijun</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Xueling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Genetics, School of Basic Medical Sciences, Guangxi Medical University, Nanning, 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mulin Jun</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. mulin@tmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Zeli</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Genetics, School of Basic Medical Sciences, Guangxi Medical University, Nanning, 530021, China. Tangzeli_team99@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Basic Research on Regional Diseases (Guangxi Medical University), Education Department of Guangxi Zhuang Autonomous Region, Nanning, 530021, China. Tangzeli_team99@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China. fangmin@sr.gxmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangxi Clinical Research Center for Anesthesiology, Guangxi Medical University Cancer Hospital, Nanning, 530021, Guangxi, China. fangmin@sr.gxmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2020KY03018</GrantID><Agency>Promotion Ability Project of Young Teachers in Guangxi Universities</Agency><Country/></Grant><Grant><GrantID>Z20211408</GrantID><Agency>the Self-raised Scientific Research Fund of the Ministry of Health of Guangxi Province</Agency><Country/></Grant><Grant><GrantID>82360410</GrantID><Agency>National Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>2024GXNSFAA010212</GrantID><Agency>National Science Foundation of Guangxi</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Parasit Vectors</MedlineTA><NlmUniqueID>101462774</NlmUniqueID><ISSNLinking>1756-3305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002843">Chromatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003004" MajorTopicYN="Y">Clonorchis sinensis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002843" MajorTopicYN="Y">Chromatin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003003" MajorTopicYN="Y">Clonorchiasis</DescriptorName><QualifierName UI="Q000469" MajorTopicYN="N">parasitology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044127" MajorTopicYN="N">Epigenesis, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042002" MajorTopicYN="Y">Chromatin Assembly and Disassembly</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clonorchis sinensis</Keyword><Keyword MajorTopicYN="N">Chromatin accessibility</Keyword><Keyword MajorTopicYN="N">Hepatocellular carcinoma</Keyword><Keyword MajorTopicYN="N">Transcription factor</Keyword><Keyword MajorTopicYN="N">Tumor progression</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: This study received approval from the Ethics Committee of the Affiliated Cancer Hospital of Guangxi Medical University (LW. 2024093) and adhered to the ethical guidelines set forth in the Helsinki Declaration of 1964. To safeguard patient confidentiality, individuals&#x2019; identities in this study were anonymized using computer-generated ID numbers. Upon admission, all patients provided written consent for the analysis and publication of their anonymized medical data for research purposes. Consent for publication: All authors have approved the manuscript for submission. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>23</Hour><Minute>55</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40640964</ArticleId><ArticleId IdType="doi">10.1186/s13071-025-06909-6</ArticleId><ArticleId IdType="pii">10.1186/s13071-025-06909-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2024;74:229&#x2013;63. https://doi.org/10.3322/caac.21834 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21834</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. International trends in hepatocellular carcinoma incidence, 1978&#x2013;2012. Int J Cancer. 2020;147:317&#x2013;30. https://doi.org/10.1002/ijc.32723 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.32723</ArticleId><ArticleId IdType="pubmed">31597196</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepatocellular carcinoma. Nature reviews Disease primers. 2021;7:7; https://doi.org/10.1038/s41572-021-00245-6 .</Citation></Reference><Reference><Citation>Arora N, Kaur R, Anjum F, Tripathi S, Mishra A, Kumar R, et al. Neglected agent eminent disease: linking human helminthic infection, inflammation, and malignancy. Front Cell Infect Microbiol. 2019;9:402. https://doi.org/10.3389/fcimb.2019.00402 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2019.00402</ArticleId><ArticleId IdType="pubmed">31867284</ArticleId><ArticleId IdType="pmc">6909818</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens&#x2013;Part B: biological agents. Lancet Oncol. 2009;10:321&#x2013;2. https://doi.org/10.1016/s1470-2045(09)70096-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1470-2045(09)70096-8</ArticleId><ArticleId IdType="pubmed">19350698</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang ZL, Huang Y, Yu XB. Current status and perspectives of Clonorchis sinensis and clonorchiasis: epidemiology, pathogenesis, omics, prevention and control. Infect Dis Poverty. 2016;5:71. https://doi.org/10.1186/s40249-016-0166-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-016-0166-1</ArticleId><ArticleId IdType="pubmed">27384714</ArticleId><ArticleId IdType="pmc">4933995</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian MB, Zhou XN. Clonorchis sinensis. Trends Parasitol. 2021;37:1014&#x2013;5. https://doi.org/10.1016/j.pt.2021.05.011 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pt.2021.05.011</ArticleId><ArticleId IdType="pubmed">34229953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Q, Tang Z, Qin Y, Deng X, Wei C, Liu F, et al. Clonorchis sinensis infection amplifies hepatocellular carcinoma stemness, predicting unfavorable prognosis. PLoS Negl Trop Dis. 2024;18:e0011906. https://doi.org/10.1371/journal.pntd.0011906 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0011906</ArticleId><ArticleId IdType="pubmed">38285640</ArticleId><ArticleId IdType="pmc">10824460</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi Y, Hu J, Liang J, Hu X, Ma N, Xiang B. Clonorchis sinensis infection contributes to hepatocellular carcinoma progression in rat. Parasitol Res. 2022;121:3403&#x2013;15. https://doi.org/10.1007/s00436-022-07699-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00436-022-07699-x</ArticleId><ArticleId IdType="pubmed">36266591</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni HH, Lu Z, Yang CL, Lv YT, Lu CX, Xiang BD. Clonorchis sinensis on the prognosis of patients with spontaneous rupture of hepatocellular carcinoma: an inverse probability of treatment weighting analysis. PLoS Negl Trop Dis. 2024;18:e0011987. https://doi.org/10.1371/journal.pntd.0011987 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0011987</ArticleId><ArticleId IdType="pubmed">38381766</ArticleId><ArticleId IdType="pmc">10911612</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YK, Zhao JF, Yang CL, Zhan GH, Zhang J, Qin SD, et al. Effects of Clonorchis sinensis combined with hepatitis B virus infection on the prognosis of patients with hepatocellular carcinoma following hepatectomy. PLoS Negl Trop Dis. 2023;17:e0011012. https://doi.org/10.1371/journal.pntd.0011012 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0011012</ArticleId><ArticleId IdType="pubmed">36638133</ArticleId><ArticleId IdType="pmc">9879467</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Lei H, Tian Y, Shang M, Wu Y, Li Y, et al. Clonorchis sinensis granulin: identification, immunolocalization, and function in promoting the metastasis of cholangiocarcinoma and hepatocellular carcinoma. Parasit Vectors. 2017;10:262. https://doi.org/10.1186/s13071-017-2179-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13071-017-2179-4</ArticleId><ArticleId IdType="pubmed">28545547</ArticleId><ArticleId IdType="pmc">5445496</ArticleId></ArticleIdList></Reference><Reference><Citation>Dechassa ML, Tryndyak V, de Conti A, Xiao W, Beland FA, Pogribny IP. Identification of chromatin-accessible domains in non-alcoholic steatohepatitis-derived hepatocellular carcinoma. Mol Carcinog. 2018;57:978&#x2013;87. https://doi.org/10.1002/mc.22818 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mc.22818</ArticleId><ArticleId IdType="pubmed">29603380</ArticleId></ArticleIdList></Reference><Reference><Citation>Casamassimi A, Ciccodicola A, Rienzo M. Transcriptional regulation and its misregulation in human diseases. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms24108640 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24108640</ArticleId><ArticleId IdType="pubmed">37239985</ArticleId><ArticleId IdType="pmc">10218156</ArticleId></ArticleIdList></Reference><Reference><Citation>Vervoort SJ, Devlin JR, Kwiatkowski N, Teng M, Gray NS, Johnstone RW. Targeting transcription cycles in cancer. Nat Rev Cancer. 2022;22:5&#x2013;24. https://doi.org/10.1038/s41568-021-00411-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-021-00411-8</ArticleId><ArticleId IdType="pubmed">34675395</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai LY, Chen SJ, Xiao SH, Sun QJ, Ding CH, Zheng BN, et al. Targeting p300/CBP attenuates hepatocellular carcinoma progression through epigenetic regulation of metabolism. Can Res. 2021;81:860&#x2013;72. https://doi.org/10.1158/0008-5472.Can-20-1323 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.Can-20-1323</ArticleId></ArticleIdList></Reference><Reference><Citation>Corces MR, Granja JM, Shams S, Louie BH, Seoane JA, Zhou W, et al. The chromatin accessibility landscape of primary human cancers. Science (New York, NY). 2018. https://doi.org/10.1126/science.aav1898 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav1898</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig AJ, Silveira MAD, Ma L, Revsine M, Wang L, Heinrich S, et al. Genome-wide profiling of transcription factor activity in primary liver cancer using single-cell ATAC sequencing. Cell Rep. 2023;42:113446. https://doi.org/10.1016/j.celrep.2023.113446 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.113446</ArticleId><ArticleId IdType="pubmed">37980571</ArticleId><ArticleId IdType="pmc">10750269</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush SJ. Read trimming has minimal effect on bacterial SNP-calling accuracy. Microbial Genomics. 2020. https://doi.org/10.1099/mgen.0.000434 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000434</ArticleId><ArticleId IdType="pubmed">33332257</ArticleId><ArticleId IdType="pmc">8116680</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B. Aligning short sequencing reads with Bowtie. Curr Protoc Bioinform. 2010. https://doi.org/10.1002/0471250953.bi1107s32 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471250953.bi1107s32</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarasov A, Vilella AJ, Cuppen E, Nijman IJ, Prins P. Sambamba: fast processing of NGS alignment formats. Bioinformatics (Oxford, England). 2015;31:2032&#x2013;4. https://doi.org/10.1093/bioinformatics/btv098 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv098</ArticleId><ArticleId IdType="pubmed">25697820</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JT, Thorvaldsd&#xf3;ttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29:24&#x2013;6. https://doi.org/10.1038/nbt.1754 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1754</ArticleId><ArticleId IdType="pubmed">21221095</ArticleId><ArticleId IdType="pmc">3346182</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https://doi.org/10.1186/s13059-014-0550-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId><ArticleId IdType="pmc">4302049</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Li M, Wu T, Zhan L, Li L, Chen M, et al. Exploring Epigenomic Datasets by ChIPseeker. Curr Protoc. 2022;2:e585. https://doi.org/10.1002/cpz1.585 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpz1.585</ArticleId><ArticleId IdType="pubmed">36286622</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Hu E, Cai Y, Xie Z, Luo X, Zhan L, et al. Using clusterProfiler to characterize multiomics data. Nat Protoc. 2024;19:3292&#x2013;320. https://doi.org/10.1038/s41596-024-01020-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-024-01020-z</ArticleId><ArticleId IdType="pubmed">39019974</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics (Oxford, England). 2014;30:923&#x2013;30. https://doi.org/10.1093/bioinformatics/btt656 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt656</ArticleId><ArticleId IdType="pubmed">24227677</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Sun Z, Wang J, Huang H, Kocher JP, Wang L. CrossMap: a versatile tool for coordinate conversion between genome assemblies. Bioinformatics (Oxford, England). 2014;30:1006&#x2013;7. https://doi.org/10.1093/bioinformatics/btt730 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btt730</ArticleId><ArticleId IdType="pubmed">24351709</ArticleId></ArticleIdList></Reference><Reference><Citation>Du D, Liu C, Qin M, Zhang X, Xi T, Yuan S, et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta pharmaceutica Sinica B. 2022;12:558&#x2013;80. https://doi.org/10.1016/j.apsb.2021.09.019 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.09.019</ArticleId><ArticleId IdType="pubmed">35256934</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra YG, Manavathi B. Focal adhesion dynamics in cellular function and disease. Cell Signal. 2021;85:110046. https://doi.org/10.1016/j.cellsig.2021.110046 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2021.110046</ArticleId><ArticleId IdType="pubmed">34004332</ArticleId></ArticleIdList></Reference><Reference><Citation>Mierke CT. The matrix environmental and cell mechanical properties regulate cell migration and contribute to the invasive phenotype of cancer cells. Rep Progr Phys Phys Soc (Great Britain). 2019;82:064602. https://doi.org/10.1088/1361-6633/ab1628 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1361-6633/ab1628</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Zhang M, Ma Z, Yuan D, Zhu J, Tuo B, et al. Alteration and dysfunction of ion channels/transporters in a hypoxic microenvironment results in the development and progression of gastric cancer. Cell Oncol (Dordrecht, Netherlands). 2021;44:739&#x2013;49. https://doi.org/10.1007/s13402-021-00604-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13402-021-00604-1</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva GB, Braga GC, Sim&#xf5;es JLB, Bagatini MD, Kempka AP. Mitochondrial dysfunction and carcinogenesis: the engagement of ion channels in cancer development. Cell Calcium. 2025;128:103010. https://doi.org/10.1016/j.ceca.2025.103010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceca.2025.103010</ArticleId><ArticleId IdType="pubmed">40043325</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala G. Neuroepithelial interactions in cancer. Ann Rev Pathol. 2023;18:493&#x2013;514. https://doi.org/10.1146/annurev-pathmechdis-031521-023248 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-pathmechdis-031521-023248</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CH, Reva B, Katabi N, Wizel A, Xu H, Ho AL, et al. Sympathetic axonogenesis promotes adenoid cystic carcinoma progression. J Exp Med. 2025. https://doi.org/10.1084/jem.20242250 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20242250</ArticleId><ArticleId IdType="pubmed">40553105</ArticleId><ArticleId IdType="pmc">12187108</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Pan Y, Zhao X, Wu S, Li F, Wang Y, et al. Peroxisome proliferator-activated receptors: a key link between lipid metabolism and cancer progression. Clin Nutr (Edinburgh, Scotland). 2024;43:332&#x2013;45. https://doi.org/10.1016/j.clnu.2023.12.005 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2023.12.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner N, Wagner KD. PPAR beta/delta and the hallmarks of cancer. Cells. 2020. https://doi.org/10.3390/cells9051133 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051133</ArticleId><ArticleId IdType="pubmed">33126411</ArticleId><ArticleId IdType="pmc">7692109</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu CC, Peng D, Cai Z, Lin HK. AMPK signaling and its targeting in cancer progression and treatment. Semin Cancer Biol. 2022;85:52&#x2013;68. https://doi.org/10.1016/j.semcancer.2021.04.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2021.04.006</ArticleId><ArticleId IdType="pubmed">33862221</ArticleId></ArticleIdList></Reference><Reference><Citation>Izdebska M, Zieli&#x144;ska W, Ha&#x142;as-Wi&#x15b;niewska M, Grzanka A. Involvement of actin and actin-binding proteins in carcinogenesis. Cells. 2020. https://doi.org/10.3390/cells9102245 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9102245</ArticleId><ArticleId IdType="pubmed">33036298</ArticleId><ArticleId IdType="pmc">7600575</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesnokova V, Melmed S. Peptide hormone regulation of DNA damage responses. Endocr Rev. 2020. https://doi.org/10.1210/endrev/bnaa009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endrev/bnaa009</ArticleId><ArticleId IdType="pubmed">32270196</ArticleId><ArticleId IdType="pmc">7279704</ArticleId></ArticleIdList></Reference><Reference><Citation>Neganova ME, Klochkov SG, Aleksandrova YR, Aliev G. Histone modifications in epigenetic regulation of cancer: perspectives and achieved progress. Semin Cancer Biol. 2022;83:452&#x2013;71. https://doi.org/10.1016/j.semcancer.2020.07.015 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2020.07.015</ArticleId><ArticleId IdType="pubmed">32814115</ArticleId></ArticleIdList></Reference><Reference><Citation>Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4&#x2013;27. https://doi.org/10.1016/j.addr.2015.11.001 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2015.11.001</ArticleId><ArticleId IdType="pubmed">26562801</ArticleId></ArticleIdList></Reference><Reference><Citation>Casillo SM, Peredo AP, Perry SJ, Chung HH, Gaborski TR. Membrane pore spacing can modulate endothelial cell-substrate and cell-cell interactions. ACS Biomater Sci Eng. 2017;3:243&#x2013;8. https://doi.org/10.1021/acsbiomaterials.7b00055 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsbiomaterials.7b00055</ArticleId><ArticleId IdType="pubmed">28993815</ArticleId><ArticleId IdType="pmc">5630150</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Yamada KM, Wang S. Tissue morphogenesis through dynamic cell and matrix interactions. Ann Rev Cell Dev Biol. 2023;39:123&#x2013;44. https://doi.org/10.1146/annurev-cellbio-020223-031019 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-020223-031019</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22:48. https://doi.org/10.1186/s12943-023-01744-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-023-01744-8</ArticleId><ArticleId IdType="pubmed">36906534</ArticleId><ArticleId IdType="pmc">10007858</ArticleId></ArticleIdList></Reference><Reference><Citation>Foglia B, Turato C, Cannito S. Hepatocellular carcinoma: latest research in pathogenesis, detection and treatment. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms241512224 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241512224</ArticleId><ArticleId IdType="pubmed">37569600</ArticleId><ArticleId IdType="pmc">10419038</ArticleId></ArticleIdList></Reference><Reference><Citation>Klemm SL, Shipony Z, Greenleaf WJ. Chromatin accessibility and the regulatory epigenome. Nat Rev Genet. 2019;20:207&#x2013;20. https://doi.org/10.1038/s41576-018-0089-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-018-0089-8</ArticleId><ArticleId IdType="pubmed">30675018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv DD, Zhou LY, Tang H. Hepatocyte nuclear factor 4&#x3b1; and cancer-related cell signaling pathways: a promising insight into cancer treatment. Exp Mol Med. 2021;53:8&#x2013;18. https://doi.org/10.1038/s12276-020-00551-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-020-00551-1</ArticleId><ArticleId IdType="pubmed">33462379</ArticleId><ArticleId IdType="pmc">8080681</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Jiang L, Liu H. Forkhead Box Protein O1: Functional Diversity and Post-Translational Modification, a New Therapeutic Target? Drug Des Dev Ther. 2021;15:1851&#x2013;60. https://doi.org/10.2147/dddt.S305016 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/dddt.S305016</ArticleId></ArticleIdList></Reference><Reference><Citation>LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab. 2007;3:302&#x2013;10. https://doi.org/10.1038/ncpendmet0427 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpendmet0427</ArticleId><ArticleId IdType="pubmed">17315038</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, Vijayakumar A, Kahn BB. Metabolites as regulators of insulin sensitivity and metabolism. Nat Rev Mol Cell Biol. 2018;19:654&#x2013;72. https://doi.org/10.1038/s41580-018-0044-8 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-018-0044-8</ArticleId><ArticleId IdType="pubmed">30104701</ArticleId><ArticleId IdType="pmc">6380503</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu YY, Chang QC, Gao JF, Bao MJ, Luo HT, Song JH, et al. Multiple biochemical indices and metabolomics of Clonorchis sinensis provide a novel interpretation of biomarkers. Parasit Vectors. 2022;15:172. https://doi.org/10.1186/s13071-022-05290-y .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13071-022-05290-y</ArticleId><ArticleId IdType="pubmed">35590378</ArticleId><ArticleId IdType="pmc">9118806</ArticleId></ArticleIdList></Reference><Reference><Citation>Han S, Zhang X, Ding J, Li X, Zhang X, Jiang X, et al. Serum metabolic profiling of rats infected with Clonorchis sinensis using LC-MS/MS method. Front Cell Infect Microbiol. 2022;12:1040330. https://doi.org/10.3389/fcimb.2022.1040330 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.1040330</ArticleId><ArticleId IdType="pubmed">36683702</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Z, Wei C, Deng X, Lin Q, Hu Q, Li S, et al. Serum proteomic and metabolomic profiling of hepatocellular carcinoma patients co-infected with Clonorchis sinensis. Front Immunol. 2024;15:1489077. https://doi.org/10.3389/fimmu.2024.1489077 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1489077</ArticleId><ArticleId IdType="pubmed">39840062</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan T, Wu Y, Deng X, Li Q, Chen Y, Lv J, et al. Multi-omics approaches reveal the molecular mechanisms underlying the interaction between Clonorchis sinensis and mouse liver. Front cell Infect Microbiol. 2023;13:1286977. https://doi.org/10.3389/fcimb.2023.1286977 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2023.1286977</ArticleId><ArticleId IdType="pubmed">38076459</ArticleId><ArticleId IdType="pmc">10710275</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, Zhang Y, Lin Z, Deng X, Ren X, Huang M, et al. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma. J Hepatol. 2024;81:265&#x2013;77. https://doi.org/10.1016/j.jhep.2024.03.016 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2024.03.016</ArticleId><ArticleId IdType="pubmed">38508240</ArticleId></ArticleIdList></Reference><Reference><Citation>You F, Wang P, Yang L, Yang G, Zhao YO, Qian F, et al. ELF4 is critical for induction of type I interferon and the host antiviral response. Nat Immunol. 2013;14:1237&#x2013;46. https://doi.org/10.1038/ni.2756 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2756</ArticleId><ArticleId IdType="pubmed">24185615</ArticleId><ArticleId IdType="pmc">3939855</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacorazza HD, Miyazaki Y, Di Cristofano A, Deblasio A, Hedvat C, Zhang J, et al. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity. 2002;17:437&#x2013;49. https://doi.org/10.1016/s1074-7613(02)00422-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1074-7613(02)00422-3</ArticleId><ArticleId IdType="pubmed">12387738</ArticleId></ArticleIdList></Reference><Reference><Citation>Giridharan S, Srinivasan M. Mechanisms of NF-&#x3ba;B p65 and strategies for therapeutic manipulation. J Inflamm Res. 2018;11:407&#x2013;19. https://doi.org/10.2147/jir.S140188 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/jir.S140188</ArticleId><ArticleId IdType="pubmed">30464573</ArticleId><ArticleId IdType="pmc">6217131</ArticleId></ArticleIdList></Reference><Reference><Citation>Abhimanyu, Ontiveros CO, Guerra-Resendez RS, Nishiguchi T, Ladki M, Hilton IB, et al. Reversing post-infectious epigenetic-mediated immune suppression. Front Immunol. 2021;12:688132. https://doi.org/10.3389/fimmu.2021.688132 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.688132</ArticleId><ArticleId IdType="pubmed">34163486</ArticleId><ArticleId IdType="pmc">8215363</ArticleId></ArticleIdList></Reference><Reference><Citation>Kan S, Li Q, Li HM, Yao YH, Du XY, Wu CY, et al. Clonorchis sinensis infection modulates key cytokines for essential immune response impacted by sex. PLoS Negl Trop Dis. 2022;16:e0010726. https://doi.org/10.1371/journal.pntd.0010726 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0010726</ArticleId><ArticleId IdType="pubmed">36083861</ArticleId><ArticleId IdType="pmc">9462580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Shi M, Zhou L, Sun H, Zhang X, He L, et al. Clonorchis sinensis adult-derived proteins elicit Th2 immune responses by regulating dendritic cells via mannose receptor. PLoS Negl Trop Dis. 2018;12:e0006251. https://doi.org/10.1371/journal.pntd.0006251 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0006251</ArticleId><ArticleId IdType="pubmed">29505573</ArticleId><ArticleId IdType="pmc">5854424</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Wei C, Huang W, Huang T, Zhou L, Xu Y, et al. Clonorchis sinensis-infected hepatocellular carcinoma exhibits distinct tumor microenvironment and molecular features. Front Immunol. 2025;16:1526699. https://doi.org/10.3389/fimmu.2025.1526699 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2025.1526699</ArticleId><ArticleId IdType="pubmed">40165955</ArticleId><ArticleId IdType="pmc">11955701</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Pang L, Dai W, Wu S, Ren T, Duan Y, et al. Role of forkhead box O proteins in hepatocellular carcinoma biology and progression (review). Front Oncol. 2021;11:667730. https://doi.org/10.3389/fonc.2021.667730 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2021.667730</ArticleId><ArticleId IdType="pubmed">34123834</ArticleId><ArticleId IdType="pmc">8190381</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Su K, Lin H, Cen B, Zheng S, Xu X. Identification and verification of a novel MAGI2-AS3/miRNA-374-5p/FOXO1 network associated with HBV-related HCC. Cells. 2022. https://doi.org/10.3390/cells11213466 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11213466</ArticleId><ArticleId IdType="pubmed">36611997</ArticleId><ArticleId IdType="pmc">9818076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Shang P, Xu C, Dong W, Zhang X, Xia Y, et al. Novel genetic alterations in liver cancer distinguish distinct clinical outcomes and combination immunotherapy responses. Front Pharmacol. 2024;15:1416295. https://doi.org/10.3389/fphar.2024.1416295 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2024.1416295</ArticleId><ArticleId IdType="pubmed">38948469</ArticleId><ArticleId IdType="pmc">11211383</ArticleId></ArticleIdList></Reference><Reference><Citation>Creyghton MP, Cheng AW, Welstead GG, Kooistra T, Carey BW, Steine EJ, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci USA. 2010;107:21931&#x2013;6. https://doi.org/10.1073/pnas.1016071107 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1016071107</ArticleId><ArticleId IdType="pubmed">21106759</ArticleId><ArticleId IdType="pmc">3003124</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajderkar S, Barozzi I, Zhu Y, Hu R, Zhang Y, Li B, et al. Topologically associating domain boundaries are required for normal genome function. Commun Biol. 2023;6:435. https://doi.org/10.1038/s42003-023-04819-w .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-023-04819-w</ArticleId><ArticleId IdType="pubmed">37081156</ArticleId><ArticleId IdType="pmc">10119121</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40640962</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">0717-6287</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Biological research</Title><ISOAbbreviation>Biol Res</ISOAbbreviation></Journal><ArticleTitle>Pharmacological evaluation of physcion as a TRPV1 inhibitor with multimodal analgesic efficacy in experimental pain models.</ArticleTitle><Pagination><StartPage>48</StartPage><MedlinePgn>48</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40659-025-00630-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pain serves as a vital protective mechanism triggered by tissue damage. While NSAIDs and opioids offer relief, their prolonged usage is hindered by adverse effects. Developing analgesics with fewer side effects is crucial for effective pain treatment. The TRPV1 channel is a key target for pain relief, with its inhibitors effectively reducing hyperalgesia in animals. This research utilized virtual screening to identify TRPV1-selective natural compounds for potent analgesic properties.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The physcion exhibited the notable affinity for TRPV1 compared to the compounds examined. After conducting molecular dynamics simulations, physcion emerged as the compound demonstrating the highest binding affinity towards TRPV1, a finding corroborated by calcium imaging, which validated its inhibitory impact. Furthermore, physcion mitigated the stretch number in the acetic acid-induced stretching model, prolonged the latency period in the hot water tail-flick and hot plate assays, and heightened the pain withdrawal threshold lowered by complete Freund's adjuvant (CFA). Notably, physcion exerted a marked effect in ameliorating bone cancer-induced pain in the hot plate and von Frey tests. Additionally, physcion diminished the levels of inflammatory cytokines and the mRNA expression of both inflammatory and calcium-related genes in the CFA-induced murine model. Furthermore, physcion downregulated the expression of inflammatory genes induced by tumor necrosis factor-&#x3b1; (TNF-&#x3b1;) in RAW264.7 cells. The underlying mechanism potentially involves the suppression of the NF-&#x3ba;B and MAPK signaling cascades.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our investigation underscores the potential of physcion as a promising candidate for analgesic therapy.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Hanbin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Li</LastName><ForeName>Guanghong</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Cardiology, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shuli</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Songqiang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Affiliated Hospital of Hunan University, Hunan University, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Simon Ming-Yuen</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PolyU-BGI Joint Research Centre for Genomics and Synthetic Biology in Global Ocean Resources, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Centre for Chinese Medicine Innovation, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Chemical Biology and Drug Discovery, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute for Future Food, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute for Smart Ageing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nie</LastName><ForeName>Xiaowei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Human Cell Biology and Genetics, School of Medicine, Southern University of Science and Technology, Shenzhen, China. niexw@sustech.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Jin-Song</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Joint Laboratory of Guangdong-Hong Kong Universities for Vascular Homeostasis and Diseases, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, China. bianjs@sustech.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KQTD20200820113040070</GrantID><Agency>Shenzhen Science and Technology Program, Shenzhen, China</Agency><Country/></Grant><Grant><GrantID>2023M731524</GrantID><Agency>China Postdoctoral Science Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biol Res</MedlineTA><NlmUniqueID>9308271</NlmUniqueID><ISSNLinking>0716-9760</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050916">TRPV Cation Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000700">Analgesics</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493921">TRPV1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050916" MajorTopicYN="Y">TRPV Cation Channels</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000700" MajorTopicYN="Y">Analgesics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="Y">Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aanalgesic</Keyword><Keyword MajorTopicYN="N">Anti-inflammation</Keyword><Keyword MajorTopicYN="N">Molecular dynamics simulation</Keyword><Keyword MajorTopicYN="N">Physcion</Keyword><Keyword MajorTopicYN="N">Virtual screening</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: All animal procedures were carried out using protocols approved by the Institutional Animal Care and Use Committee of the Southern University of Science and Technology. Adherence to the prescribed protocols and guidelines concerning the ethical treatment of animals was rigorously upheld throughout the study period (SUSTech-JY202404012). Consent for publication: Not applicable. Competing interests: None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>23</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40640962</ArticleId><ArticleId IdType="doi">10.1186/s40659-025-00630-5</ArticleId><ArticleId IdType="pii">10.1186/s40659-025-00630-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kong H, Jiang CY, Hu L, Teng P, Zhang Y, Pan XX, Sun XD, Liu WT. Morphine induces dysfunction of PINK1/Parkin-mediated mitophagy in spinal cord neurons implying involvement in antinociceptive tolerance. J Mol Cell Biol. 2019;11(12):1056&#x2013;68. https://doi.org/10.1093/jmcb/mjz002 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jmcb/mjz002</ArticleId><ArticleId IdType="pubmed">30698724</ArticleId><ArticleId IdType="pmc">7261486</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiff PL. Opium and Its Alkaloids. In: 2004.</Citation></Reference><Reference><Citation>Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R. Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">18443635</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones MR, Viswanath O, Peck J, Kaye AD, Gill JS, Simopoulos TT. A brief history of the opioid epidemic and strategies for pain medicine. Pain Ther. 2018;7(1):13&#x2013;21. https://doi.org/10.1007/s40122-018-0097-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40122-018-0097-6</ArticleId><ArticleId IdType="pubmed">29691801</ArticleId><ArticleId IdType="pmc">5993682</ArticleId></ArticleIdList></Reference><Reference><Citation>Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389(6653):816&#x2013;24. https://doi.org/10.1038/39807 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/39807</ArticleId><ArticleId IdType="pubmed">9349813</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia R, Samad TA, Btesh J, Jiang LH, Kays I, Stjernborg L, Dekker N. TRPV1 signaling: mechanistic Understanding and therapeutic potential. Curr Top Med Chem 2011;11(17):2180&#x2013;91. https://doi.org/10.2174/156802611796904843</Citation></Reference><Reference><Citation>Arnold WR, Mancino A, Moss FR 3rd, Frost A, Julius D, Cheng Y. Structural basis of TRPV1 modulation by endogenous bioactive lipids. Nat Struct Mol Biol. 2024;31(9):1377&#x2013;85. https://doi.org/10.1038/s41594-024-01299-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-024-01299-2</ArticleId><ArticleId IdType="pubmed">38698206</ArticleId><ArticleId IdType="pmc">11402599</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Xiao X, Cheng W, Yang W, Yu P, Song Z, Yarov-Yarovoy V, Zheng J. Structural mechanism underlying capsaicin binding and activation of the TRPV1 ion channel. Nat Chem Biol 2015;11(7):518&#x2013;24. https://doi.org/10.1038/nchembio.1835</Citation></Reference><Reference><Citation>D&#xed;az-Franulic I, Caceres-Molina J, Sepulveda RV, Gonzalez-Nilo F, Latorre R. Structure-Driven Pharmacology of transient receptor potential channel vanilloid 1. Mol Pharmacol. 2016;90(3):300&#x2013;8. https://doi.org/10.1124/mol.116.104430 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.116.104430</ArticleId><ArticleId IdType="pubmed">27335334</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann D, Pakfeifer P, Hering S, Ecker GF. Novel scaffolds for modulation of TRPV1 identified with pharmacophore modeling and virtual screening. Future Med Chem 2015;7(3):243&#x2013;56. https://doi.org/10.4155/fmc.14.168</Citation></Reference><Reference><Citation>Andrei C, Mihai DP, Zanfirescu A, Nitulescu GM, Negres S. In Silico Drug Repurposing Framework Predicts Repaglinide, Agomelatine and Protokylol as TRPV1 Modulators with Analgesic Activity. Pharmaceutics 2022, 14(12). https://doi.org/10.3390/pharmaceutics14122563</Citation></Reference><Reference><Citation>Nisbet LJ. M Moore Will natural products remain an important source of drug research for the future? Curr Opin Biotechnol 1997;8(6) 708&#x2013;12 https://doi.org/10.1016/s0958-1669(97)80124-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0958-1669(97)80124-3</ArticleId><ArticleId IdType="pubmed">9425661</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadybekov AV, Katritch V. Computational approaches streamlining drug discovery. Nature. 2023;616(7958):673&#x2013;85. https://doi.org/10.1038/s41586-023-05905-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-05905-z</ArticleId><ArticleId IdType="pubmed">37100941</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov. 2021;20(3):200&#x2013;16. https://doi.org/10.1038/s41573-020-00114-z .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-00114-z</ArticleId><ArticleId IdType="pubmed">33510482</ArticleId><ArticleId IdType="pmc">7841765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropp PJ, Spiegel JO, Walker JL, Green H, Morales GA, Milliken KA, Ringe JJ, Durrant JD. Gypsum-DL: an open-source program for Preparing small-molecule libraries for structure-based virtual screening. J Cheminform. 2019;11(1):34. https://doi.org/10.1186/s13321-019-0358-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13321-019-0358-3</ArticleId><ArticleId IdType="pubmed">31127411</ArticleId><ArticleId IdType="pmc">6534830</ArticleId></ArticleIdList></Reference><Reference><Citation>Ropp PJ, Kaminsky JC, Yablonski S, Durrant JD. Dimorphite-DL: an open-source program for enumerating the ionization States of drug-like small molecules. J Cheminform. 2019;11(1):14. https://doi.org/10.1186/s13321-019-0336-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13321-019-0336-9</ArticleId><ArticleId IdType="pubmed">30767086</ArticleId><ArticleId IdType="pmc">6689865</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J, Tang S, Mei Z, Wang L, Huang Q, Hu H, Ling M, Wu J. Vina-GPU 2.0: further accelerating AutoDock Vina and its derivatives with graphics processing units. J Chem Inf Model. 2023;63(7):1982&#x2013;98. https://doi.org/10.1021/acs.jcim.2c01504 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.2c01504</ArticleId><ArticleId IdType="pubmed">36941232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem 2008;29(11):1859&#x2013;65. https://doi.org/10.1002/jcc.20945</Citation></Reference><Reference><Citation>Wu EL, Cheng X, Jo S, Rui H, Song KC, D&#xe1;vila-Contreras EM, Qi Y, Lee J, Monje-Galvan V, Venable RM et al. CHARMM-GUI membrane builder toward realistic biological membrane simulations. J Comput Chem 2014;35(27):1997&#x2013;2004. https://doi.org/10.1002/jcc.23702</Citation></Reference><Reference><Citation>Huang J, Rauscher S, Nawrocki G, Ran T, Feig M, de Groot BL, Grubm&#xfc;ller H, MacKerell AD. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat Methods 2017;14(1):71&#x2013;3. https://doi.org/10.1038/nmeth.4067</Citation></Reference><Reference><Citation>Adasme MF, Linnemann KL, Bolz SN, Kaiser F, Salentin S, Haupt VJ, Schroeder M. PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 2021;49(W1):W530&#x2013;4. https://doi.org/10.1093/nar/gkab294 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab294</ArticleId><ArticleId IdType="pubmed">33950214</ArticleId><ArticleId IdType="pmc">8262720</ArticleId></ArticleIdList></Reference><Reference><Citation>Vald&#xe9;s-Tresanco MS, Vald&#xe9;s-Tresanco ME, Valiente PA, Moreno E. gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS. J Chem Theory Comput. 2021;17(10):6281&#x2013;91. https://doi.org/10.1021/acs.jctc.1c00645 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.1c00645</ArticleId><ArticleId IdType="pubmed">34586825</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J. gmxtools. Zenodo 2022. https://doi.org/10.5281/zenodo.6408973</Citation></Reference><Reference><Citation>Schrodinger LLC. The PyMOL Molecular Graphics System, Version 1.8. In.;2015.</Citation></Reference><Reference><Citation>Wang X, Liao Q, Chen H, Gong G, Siu SWI, Chen Q, Kam H, Ung COL, Cheung KK, R&#xe1;dis-Baptista G, et al. Toxic peptide from Palythoa Caribaeorum acting on the TRPV1 channel prevents Pentylenetetrazol-Induced epilepsy in zebrafish larvae. Front Pharmacol. 2021;12:763089. https://doi.org/10.3389/fphar.2021.763089 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.763089</ArticleId><ArticleId IdType="pubmed">34925021</ArticleId><ArticleId IdType="pmc">8672801</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagdas D, Muldoon PP, AlSharari S, Carroll FI, Negus SS, Damaj MI. Expression and Pharmacological modulation of visceral pain-induced conditioned place aversion in mice. Neuropharmacology. 2016;102:236&#x2013;43. https://doi.org/10.1016/j.neuropharm.2015.11.024 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2015.11.024</ArticleId><ArticleId IdType="pubmed">26639043</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Ip CK, Lee IJ, Qi Y, Reed F, Karl T, Low JK, Enriquez RF, Lee NJ, Baldock PA et al. Diet-induced adaptive thermogenesis requires neuropeptide FF receptor-2 signalling. Nat Commun 2018;9(1):4722. https://doi.org/10.1038/s41467-018-06462-0</Citation></Reference><Reference><Citation>Neelakantan H, Tallarida RJ, Reichenbach ZW, Tuma RF, Ward SJ, Walker EA. Distinct interactions of Cannabidiol and morphine in three nociceptive behavioral models in mice. Behav Pharmacol. 2015;26(3):304&#x2013;14. https://doi.org/10.1097/fbp.0000000000000119 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/fbp.0000000000000119</ArticleId><ArticleId IdType="pubmed">25485642</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson AA, Brown DR, el-Atrash S, Walser MM. Pain threshold changes in adjuvant-induced inflammation: a possible model of chronic pain in the mouse. Pharmacol Biochem Behav. 1986;24(1):49&#x2013;53. https://doi.org/10.1016/0091-3057(86)90043-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0091-3057(86)90043-2</ArticleId><ArticleId IdType="pubmed">3945666</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods. 1994;53(1):55&#x2013;63. https://doi.org/10.1016/0165-0270(94)90144-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-0270(94)90144-9</ArticleId><ArticleId IdType="pubmed">7990513</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, Gu Y, Liao Y, Bang S, Donnelly CR, Chen O, Tao X, Mirando AJ, Hilton MJ, Ji RR. PD-1 Blockade inhibits osteoclast formation and murine bone cancer pain. J Clin Invest. 2020;130(7):3603&#x2013;20. https://doi.org/10.1172/jci133334 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci133334</ArticleId><ArticleId IdType="pubmed">32484460</ArticleId><ArticleId IdType="pmc">7324182</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ. TD Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402&#x2013;8 https://doi.org/10.1006/meth.2001.1262 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/meth.2001.1262</ArticleId><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuberger A, Oda M, Nikolaev YA, Nadezhdin KD, Gracheva EO, Bagriantsev SN, Sobolevsky AI. Human TRPV1 structure and Inhibition by the analgesic SB-366791. Nat Commun. 2023;14(1):2451. https://doi.org/10.1038/s41467-023-38162-9 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38162-9</ArticleId><ArticleId IdType="pubmed">37117175</ArticleId><ArticleId IdType="pmc">10147690</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Cao E, Julius D, Cheng Y. TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid action. Nat 2016, 534(7607):347&#x2013;51. https://doi.org/10.1038/nature17964</Citation></Reference><Reference><Citation>Al-Khafaji K, Taskin Tok T. Molecular dynamics simulation, free energy landscape and binding free energy computations in exploration the anti-invasive activity of amygdalin against metastasis. Comput Methods Programs Biomed. 2020;195:105660. https://doi.org/10.1016/j.cmpb.2020.105660 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2020.105660</ArticleId><ArticleId IdType="pubmed">32726718</ArticleId></ArticleIdList></Reference><Reference><Citation>Papaleo E, Mereghetti P, Fantucci P, Grandori R, De Gioia L. Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: the myoglobin case. J Mol Graph Model. 2009;27(8):889&#x2013;99. https://doi.org/10.1016/j.jmgm.2009.01.006 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmgm.2009.01.006</ArticleId><ArticleId IdType="pubmed">19264523</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustos D, Galarza C, Ordo&#xf1;ez W, Brauchi S, Benso B. Cost-Effective pipeline for a rational design and selection of capsaicin analogues targeting TRPV1 channels. ACS Omega. 2023;8(13):11736&#x2013;49. https://doi.org/10.1021/acsomega.2c05672 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsomega.2c05672</ArticleId><ArticleId IdType="pubmed">37033853</ArticleId><ArticleId IdType="pmc">10077575</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua T, Wang H, Fan X, An N, Li J, Song H, Kong E, Li Y, Yuan H. BRD4 Inhibition attenuates inflammatory pain by ameliorating NLRP3 Inflammasome-Induced pyroptosis. Front Immunol. 2022;13:837977. https://doi.org/10.3389/fimmu.2022.837977 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.837977</ArticleId><ArticleId IdType="pubmed">35154163</ArticleId><ArticleId IdType="pmc">8826720</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Yan H, Li X, Liu J, Cao S, Huang B, Huang D, Wu L. Inhibition of connexin 43 and phosphorylated NR2B in spinal astrocytes attenuates bone Cancer pain in mice. Front Cell Neurosci. 2018;12(129). https://doi.org/10.3389/fncel.2018.00129 .</Citation></Reference><Reference><Citation>Wu Z, Cai Z, Shi H, Huang X, Cai M, Yuan K, Huang P, Shi G, Yan T, Li Z. Effective biomarkers and therapeutic targets of nerve-immunity interaction in the treatment of depression: an integrated investigation of the miRNA-mRNA regulatory networks. Aging. 2022;14(8):3569&#x2013;96. https://doi.org/10.18632/aging.204030 .</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.204030</ArticleId><ArticleId IdType="pubmed">35468096</ArticleId><ArticleId IdType="pmc">9085226</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung JE, Eskew O, Wong T, Tchivileva IE, Oladosu FA, O&#x2019;Buckley SC, Nackley AG. Nuclear factor-kappa B regulates pain and COMT expression in a rodent model of inflammation. Brain Behav Immun 2015;50:196&#x2013;202. https://doi.org/10.1016/j.bbi.2015.07.014</Citation></Reference><Reference><Citation>Yang F, Xiao X, Lee BH, Vu S, Yang W, Yarov-Yarovoy V, Zheng J. The conformational wave in capsaicin activation of transient receptor potential vanilloid 1 ion channel. Nat Commun 2018;9(1):2879. https://doi.org/10.1038/s41467-018-05339-6</Citation></Reference><Reference><Citation>Yin Y, Dong Y, Vu S, Yang F, Yarov-Yarovoy V, Tian Y, Zheng J. Structural mechanisms underlying activation of TRPV1 channels by pungent compounds in gingers. Br J Pharmacol. 2019;176(17):3364&#x2013;77. https://doi.org/10.1111/bph.14766 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14766</ArticleId><ArticleId IdType="pubmed">31207668</ArticleId><ArticleId IdType="pmc">6692589</ArticleId></ArticleIdList></Reference><Reference><Citation>Talyzina IA, Nadezhdin KD, Sobolevsky AI. Forty sites of TRP channel regulation. Curr Opin Chem Biol. 2025;84:102550. https://doi.org/10.1016/j.cbpa.2024.102550 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbpa.2024.102550</ArticleId><ArticleId IdType="pubmed">39615427</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Huang Y-h, Yang M-l. Lin Z-q: Emodin ameliorates diabetic neuropathic pain through inhibiting up-regulation of TRPV1 and pro-inflammatory cytokines in dorsal root ganglions in rats. In: 2020.</Citation></Reference><Reference><Citation>XunLi, Liu Y, Chu S, Yang S, Peng Y, Ren S, Wen B, Chen N. Physcion and physcion 8-O-&#x3b2;-glucopyranoside: A review of their pharmacology, toxicities and pharmacokinetics. Chem Biol Interact 2019;310:108722. https://doi.org/10.1016/j.cbi.2019.06.035</Citation></Reference><Reference><Citation>Sa&#x142;at K, Filipek B. Antinociceptive activity of transient receptor potential channel TRPV1, TRPA1, and TRPM8 antagonists in neurogenic and neuropathic pain models in mice. J Zhejiang Univ Sci B. 2015;16(3):167&#x2013;78. https://doi.org/10.1631/jzus.B1400189 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1631/jzus.B1400189</ArticleId><ArticleId IdType="pubmed">25743118</ArticleId><ArticleId IdType="pmc">4357366</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Yang C, Wang ZJ. Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential Ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience. 2011;193:440&#x2013;51. https://doi.org/10.1016/j.neuroscience.2011.06.085 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2011.06.085</ArticleId><ArticleId IdType="pubmed">21763756</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker KM, Urban L, Medhurst SJ, Patel S, Panesar M, Fox AJ, McIntyre P. The VR1 antagonist Capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2003;304(1):56&#x2013;62. https://doi.org/10.1124/jpet.102.042010 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.102.042010</ArticleId><ArticleId IdType="pubmed">12490575</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkins MN, Campbell EA. Capsazepine reversal of the antinociceptive action of capsaicin in vivo. Br J Pharmacol. 1992;107(2):329&#x2013;33. https://doi.org/10.1111/j.1476-5381.1992.tb12746.x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.1992.tb12746.x</ArticleId><ArticleId IdType="pubmed">1422585</ArticleId><ArticleId IdType="pmc">1907885</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual D, Goicoechea C, Burgos E, Mart&#xed;n MI. Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by Paclitaxel in rats. Pharmacol Biochem Behav. 2010;95(3):331&#x2013;7. https://doi.org/10.1016/j.pbb.2010.02.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbb.2010.02.009</ArticleId><ArticleId IdType="pubmed">20184918</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniazzi CTD, Nassini R, Rigo FK, Milioli AM, Bellinaso F, Camponogara C, Silva CR, de Almeida AS, Rossato MF, De Logu F, et al. Transient receptor potential Ankyrin 1 (TRPA1) plays a critical role in a mouse model of cancer pain. Int J Cancer. 2019;144(2):355&#x2013;65. https://doi.org/10.1002/ijc.31911 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.31911</ArticleId><ArticleId IdType="pubmed">30289972</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Chen F, Fang H, Mi J, Qi Q, Yang M. Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice. Biol Res. 2020;53(1):48. https://doi.org/10.1186/s40659-020-00316-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40659-020-00316-0</ArticleId><ArticleId IdType="pubmed">33081840</ArticleId><ArticleId IdType="pmc">7576854</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose M, Duhamel M, Aboulouard S, Kobeissy F, Tierny D, Fournier I, Rodet F, Salzet M. Therapeutic anti-glioma effect of the combined action of PCSK inhibitor with the anti-tumoral factors secreted by Poly (I:C)-stimulated macrophages. Cancer Gene Ther. 2022;29(1):22&#x2013;36. https://doi.org/10.1038/s41417-020-00286-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41417-020-00286-1</ArticleId><ArticleId IdType="pubmed">33402730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho KW, Lambert WS, Calkins DJ. Activation of the TRPV1 cation channel contributes to stress-induced astrocyte migration. Glia. 2014;62(9):1435&#x2013;51. https://doi.org/10.1002/glia.22691 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22691</ArticleId><ArticleId IdType="pubmed">24838827</ArticleId><ArticleId IdType="pmc">4107153</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda R, Hayashi Y, Hell JW. CaMKII: a central molecular organizer of synaptic plasticity, learning and memory. Nat Rev Neurosci. 2022;23(11):666&#x2013;82. https://doi.org/10.1038/s41583-022-00624-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-022-00624-2</ArticleId><ArticleId IdType="pubmed">36056211</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Quickelberghe E, De Sutter D, van Loo G, Eyckerman S, Gevaert K. A protein-protein interaction map of the TNF-induced NF-&#x3ba;B signal transduction pathway. Sci Data. 2018;5:180289. https://doi.org/10.1038/sdata.2018.289 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2018.289</ArticleId><ArticleId IdType="pubmed">30561431</ArticleId><ArticleId IdType="pmc">6298254</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabio G, Davis RJ. TNF and MAP kinase signalling pathways. Semin Immunol. 2014;26(3):237&#x2013;45. https://doi.org/10.1016/j.smim.2014.02.009 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2014.02.009</ArticleId><ArticleId IdType="pubmed">24647229</ArticleId><ArticleId IdType="pmc">4099309</ArticleId></ArticleIdList></Reference><Reference><Citation>Veltri A, Lang CMR, Cangiotti G, Chan CK, Lien WH. ROR2 regulates self-renewal and maintenance of hair follicle stem cells. Nat Commun. 2022;13(1):4449. https://doi.org/10.1038/s41467-022-32239-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32239-7</ArticleId><ArticleId IdType="pubmed">35915068</ArticleId><ArticleId IdType="pmc">9343661</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh GS, Pae HO, Seo WG, Kim NY, Pyun KH, Kim IK, Shin M, Chung HT. Capsazepine, a vanilloid receptor antagonist, inhibits the expression of inducible nitric oxide synthase gene in lipopolysaccharide-stimulated RAW264.7 macrophages through the inactivation of nuclear transcription factor-kappa B. Int Immunopharmacol. 2001;1(4):777&#x2013;84. https://doi.org/10.1016/s1567-5769(01)00012-1 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1567-5769(01)00012-1</ArticleId><ArticleId IdType="pubmed">11357890</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y, Yang Y, Zhao Z, Wang S, Chen X, Xie Y, Chen H, Xu J. Capsazepine inhibits astrocyte activation and attenuates neuroinflammation by targeting syntaxin 7. Faseb J. 2025;39(10):e70657. https://doi.org/10.1096/fj.202500523R .</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202500523R</ArticleId><ArticleId IdType="pubmed">40386937</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Y, Cohen BE, Chuang HH. A single TRPV1 amino acid controls species sensitivity to capsaicin. Sci Rep. 2020;10(1):8038. https://doi.org/10.1038/s41598-020-64584-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-64584-2</ArticleId><ArticleId IdType="pubmed">32415171</ArticleId><ArticleId IdType="pmc">7229161</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam PM, McDonald J, Lambert DG. Characterization and comparison of Recombinant human and rat TRPV1 receptors: effects of exo- and endocannabinoids. Br J Anaesth. 2005;94(5):649&#x2013;56. https://doi.org/10.1093/bja/aei098 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aei098</ArticleId><ArticleId IdType="pubmed">15722382</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre P, McLatchie LM, Chambers A, Phillips E, Clarke M, Savidge J, Toms C, Peacock M, Shah K, Winter J, et al. Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br J Pharmacol. 2001;132(5):1084&#x2013;94. https://doi.org/10.1038/sj.bjp.0703918 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0703918</ArticleId><ArticleId IdType="pubmed">11226139</ArticleId><ArticleId IdType="pmc">1572656</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi W, Jian-bo Y, Ying W, Yan-yi LI, Yu-jie Z, Hai-ruo WEN. Shuang-cheng MA: toxicokinetics study of physcion in rats in vivo. Chin Pharm J 2022, 57(19):1666&#x2013;72. https://doi.org/10.11669/cpj.2022.19.011</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40640959</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1474-760X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Genome biology</Title><ISOAbbreviation>Genome Biol</ISOAbbreviation></Journal><ArticleTitle>Protein quantitative trait locus analysis in African American and non-Hispanic White individuals.</ArticleTitle><Pagination><StartPage>200</StartPage><MedlinePgn>200</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13059-025-03671-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Substantial efforts have been dedicated to exploring the link between genetic regulation and the proteome, informing studies of complex trait mechanisms. Most of these efforts have been limited to populations of European ancestry.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We conduct an Olink protein quantitative trait locus (pQTL) analysis on 1245 proteins involving 1033 self-identified African American (AA) and 1764 non-Hispanic White (NHW) participants from the Women's Health Initiative and Framingham Heart Study. For replication of candidate pQTLs, we use data from 534 self-identified AA adults from the Jackson Heart Study and protein genome-wide association analysis statistics from the UK Biobank Pharma Proteomics Project, including 54,219 participants, of whom 931 are of African ancestry. In total, we identify and validate 5103 pQTLs (4496 or 88% cis- and 602 or 12% trans-pQTLs) for 983 proteins. Among these, 195 are previously unreported, with most (166 or 85%) identified in our AA sample, many of which were essentially monomorphic in European reference populations. Several of these newly identified African ancestry-specific pQTLs have been reported in ClinVar; our results suggest impact on circulating protein levels, potentially bolstering evidence for clinical significance. We identify a "cis pQTL hotspot" within the leukocyte receptor gene cluster on human chromosome 19q13.4. We also provide examples where a particular cis-pQTL, identified through conditional analysis, offers biological insights into an overlapping GWAS signal for disease susceptibility.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The identification of previously undescribed African ancestry-specific pQTLs contributes to understanding protein genetic regulation and highlights the significance of proteomic analysis in diverse populations.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Yanwei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haessler</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molstad</LastName><ForeName>Aaron J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>School of Statistics, University of Minnesota, Minneapolis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Shih-Jen</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joehanes</LastName><ForeName>Roby</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murabito</LastName><ForeName>Joanne M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tahir</LastName><ForeName>Usman A</ForeName><Initials>UA</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franceschini</LastName><ForeName>Nora</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Gillings School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerszten</LastName><ForeName>Robert E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Framingham Heart Study, Framingham, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raffield</LastName><ForeName>Laura M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kooperberg</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiner</LastName><ForeName>Alexander P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, USA. apreiner@uw.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL152439</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL152439</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL152439</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL152439</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL152439</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 HL161445-01A1</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HHSN268201600034I, HL133870</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-HG011720</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-HG011720</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Genome Biol</MedlineTA><NlmUniqueID>100960660</NlmUniqueID><ISSNLinking>1474-7596</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="Y">Quantitative Trait Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="Y">Black or African American</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="Y">White People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Olink</Keyword><Keyword MajorTopicYN="N">Proteomics</Keyword><Keyword MajorTopicYN="N">Whole genome sequencing</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval: No new ethical approval or consent was required for this study. All data were obtained from existing studies (WHI, FHS, JHS) with prior institutional review board (IRB) approval and participant consent. Competing interests: Laura M. Raffield is a consultant for the TOPMed Administrative Coordinating Center (through Westat). Nora Franceschini is a Guest Editor for the collection but remained independent of the peer review process. The other authors declare no competing interests. Peer review information: Tim Sands was the primary editor of this article and managed its editorial process and peer review in collaboration with the rest of the editorial team. The peer-review history is available in the online version of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>23</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40640959</ArticleId><ArticleId IdType="doi">10.1186/s13059-025-03671-x</ArticleId><ArticleId IdType="pii">10.1186/s13059-025-03671-x</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Emilsson V, Ilkov M, Lamb JR, Finkel N, Gudmundsson EF, Pitts R, et al. Co-regulatory networks of human serum proteins link genetics to disease. Science. 2018;361(6404):769&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">30072576</ArticleId><ArticleId IdType="pmc">6190714</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of the human plasma proteome. Nature. 2018Jun;558(7708):73&#x2013;9.2.</Citation><ArticleIdList><ArticleId IdType="pubmed">29875488</ArticleId><ArticleId IdType="pmc">6697541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, et al. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 2021;53(12):1712&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">34857953</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietzner M, Wheeler E, Carrasco-Zanini J, Cortes A, Koprulu M, W&#xf6;rheide MA, et al. Mapping the proteo-genomic convergence of human diseases. Science. 2021;374(6569):eabj1541.</Citation></Reference><Reference><Citation>Gudjonsson A, Gudmundsdottir V, Axelsson GT, Gudmundsson EF, Jonsson BG, Launer LJ, et al. A genome-wide association study of serum proteins reveals shared loci with common diseases. Nat Commun. 2022;13(1):480.</Citation><ArticleIdList><ArticleId IdType="pubmed">35078996</ArticleId><ArticleId IdType="pmc">8789779</ArticleId></ArticleIdList></Reference><Reference><Citation>Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman &#xc5;K, Schork A, et al. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nat Metab. 2020;2(10):1135&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">33067605</ArticleId><ArticleId IdType="pmc">7611474</ArticleId></ArticleIdList></Reference><Reference><Citation>Koprulu M, Carrasco-Zanini J, Wheeler E, Lockhart S, Kerrison ND, Wareham NJ, et al. Proteogenomic links to human metabolic diseases. Nat Metab. 2023;5(3):516&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">36823471</ArticleId><ArticleId IdType="pmc">7614946</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun BB, Chiou J, Traylor M, Benner C, Hsu YH, Richardson TG, et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023;622(7982):329&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">37794186</ArticleId><ArticleId IdType="pmc">10567551</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldjarn GH, Ferkingstad E, Lund SH, Helgason H, Magnusson OT, Gunnarsdottir K, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023;622(7982):348&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">37794188</ArticleId><ArticleId IdType="pmc">10567571</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz DH, Tahir UA, Bick AG, Pampana A, Ngo D, Benson MD, et al. Whole Genome Sequence Analysis of the Plasma Proteome in Black Adults Provides Novel Insights Into Cardiovascular Disease. Circulation. 2022;145(5):357&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">34814699</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Dutta D, K&#xf6;ttgen A, Tin A, Schlosser P, Grams ME, et al. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat Genet. 2022;54(5):593&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">35501419</ArticleId><ArticleId IdType="pmc">9236177</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Rasheed H, N&#xf8;st TH, Cho Y, Liu Y, Bhatta L, et al. Proteome-wide Mendelian randomization in global biobank meta-analysis reveals multi-ancestry drug targets for common diseases. Cell Genomics. 2022;2(11):None.</Citation></Reference><Reference><Citation>Sjaarda J, Gerstein HC, Kutalik Z, Mohammadi-Shemirani P, Pigeyre M, Hess S, et al. Influence of Genetic Ancestry on Human Serum Proteome. Am J Hum Genet. 2020;106(3):303&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">32059761</ArticleId><ArticleId IdType="pmc">7058828</ArticleId></ArticleIdList></Reference><Reference><Citation>Taliun D, Harris DN, Kessler MD, Carlson J, Szpiech ZA, Torres R, et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature. 2021;590(7845):290&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33568819</ArticleId><ArticleId IdType="pmc">7875770</ArticleId></ArticleIdList></Reference><Reference><Citation>Orchard P, Blackwell TW, Kachuri L, Castaldi PJ, Cho MH, Christenson SA, et al. Cross-cohort analysis of expression and splicing quantitative trait loci in TOPMed [Internet]. medRxiv; 2025 [cited 2025 Apr 29]. p. 2025.02.19.25322561. Available from: https://www.medrxiv.org/content/ https://doi.org/10.1101/2025.02.19.25322561v1</Citation></Reference><Reference><Citation>Klarin D, Busenkell E, Judy R, Lynch J, Levin M, Haessler J, et al. Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet. 2019;51(11):1574&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31676865</ArticleId><ArticleId IdType="pmc">6858581</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindstr&#xf6;m S, Wang L, Smith EN, Gordon W, van Hylckama VA, de Andrade M, et al. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. Blood. 2019;134(19):1645&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">31420334</ArticleId><ArticleId IdType="pmc">6871304</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezemer ID, Arellano AR, Tong CH, Rowland CM, Ireland HA, Bauer KA, et al. F9 Malm&#xf6;, factor IX and deep vein thrombosis. Haematologica. 2009;94(5):693&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19286883</ArticleId><ArticleId IdType="pmc">2675682</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Gupta R, Kanai M, Lu W, Tsuo K, Wang Y, et al. Pan-UK Biobank GWAS improves discovery, analysis of genetic architecture, and resolution into ancestry-enriched effects [Internet]. medRxiv; 2024 [cited 2024 Jun 5]. p. 2024.03.13.24303864. Available from: https://www.medrxiv.org/content/ https://doi.org/10.1101/2024.03.13.24303864v1</Citation></Reference><Reference><Citation>Sun C, Wu MH, Guo M, Day ML, Lee ES, Yuan SY. ADAM15 regulates endothelial permeability and neutrophil migration via Src/ERK1/2 signalling. Cardiovasc Res. 2010;87(2):348&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189953</ArticleId><ArticleId IdType="pmc">2895539</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen DW, Zhao RM, Jin Y, Zhang J, Han C, Jiang SQ, et al. Plasma soluble vascular adhesion protein-1 concentration correlates with arterial stiffness: A cross-sectional study. Arch Gerontol Geriatr. 2015;61(1):67&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">25959807</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths CE, Boffa MJ, Gallatin WM, Martin S. Elevated levels of circulating intercellular adhesion molecule-3 (cICAM-3) in Psoriasis. Acta Derm Venereol. 1996;76(1):2&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8721479</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollicone R, Reguigne I, Fletcher A, Aziz A, Rustam M, Weston BW, et al. Molecular basis for plasma alpha(1,3)-fucosyltransferase gene deficiency (FUT6). J Biol Chem. 1994;269(17):12662&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">8175676</ArticleId></ArticleIdList></Reference><Reference><Citation>Polfus LM, Raffield LM, Wheeler MM, Tracy RP, Lange LA, Lettre G, et al. Whole genome sequence association with E-selectin levels reveals loss-of-function variant in African Americans. Hum Mol Genet. 2019;28(3):515&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">30307499</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen VL, Du X, Chen Y, Kuppa A, Handelman SK, Vohnoutka RB, et al. Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology. Nat Commun. 2021;12(1):816.</Citation><ArticleIdList><ArticleId IdType="pubmed">33547301</ArticleId><ArticleId IdType="pmc">7865025</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021;53(10):1415&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">34594039</ArticleId><ArticleId IdType="pmc">12208603</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappoport N, Simon AJ, Amariglio N, Rechavi G. The Duffy antigen receptor for chemokines, ACKR1,- &#x201c;Jeanne DARC&#x201d; of benign neutropenia. Br J Haematol. 2019;184(4):497&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">30592023</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinna N, Rida P, Su T, Gong Z, Yao S, LaBarge M, et al. The DARC Side of Inflamm-Aging: Duffy Antigen Receptor for Chemokines (DARC/ACKR1) as a Potential Biomarker of Aging, Immunosenescence, and Breast Oncogenesis among High-Risk Subpopulations. Cells. 2022;11(23):3818.</Citation><ArticleIdList><ArticleId IdType="pubmed">36497078</ArticleId><ArticleId IdType="pmc">9740232</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. Cell. 2020;182(5):1214-1231.e11.</Citation><ArticleIdList><ArticleId IdType="pubmed">32888494</ArticleId><ArticleId IdType="pmc">7482360</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen MH, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, et al. Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. Cell. 2020;182(5):1198-1213.e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">32888493</ArticleId><ArticleId IdType="pmc">7480402</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurdasani D, Carstensen T, Fatumo S, Chen G, Franklin CS, Prado-Martinez J, et al. Uganda Genome Resource Enables Insights into Population History and Genomic Discovery in Africa. Cell. 2019;179(4):984-1002.e36.</Citation><ArticleIdList><ArticleId IdType="pubmed">31675503</ArticleId><ArticleId IdType="pmc">7202134</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomino DCT, Marti LC. Chemokines and immunity. Einstein Sao Paulo Braz. 2015;13(3):469&#x2013;73.</Citation></Reference><Reference><Citation>Zhao JH, Stacey D, Eriksson N, Macdonald-Dunlop E, Hedman &#xc5;K, Kalnapenkis A, et al. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat Immunol. 2023;24(9):1540&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">37563310</ArticleId><ArticleId IdType="pmc">10457199</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Haberland V, Baird D, Walker V, Haycock PC, Hurle MR, et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat Genet. 2020;52(10):1122&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">32895551</ArticleId><ArticleId IdType="pmc">7610464</ArticleId></ArticleIdList></Reference><Reference><Citation>Dostert C, Grusdat M, Letellier E, Brenner D. The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond. Physiol Rev. 2019;99(1):115&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">30354964</ArticleId></ArticleIdList></Reference><Reference><Citation>Pazoki R, Vujkovic M, Elliott J, Evangelou E, Gill D, Ghanbari M, et al. Genetic analysis in European ancestry individuals identifies 517 loci associated with liver enzymes. Nat Commun. 2021;12(1):2579.</Citation><ArticleIdList><ArticleId IdType="pubmed">33972514</ArticleId><ArticleId IdType="pmc">8110798</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashita T, Kawakami A, Nakashima T, Yamasaki S, Tamai M, Tanaka F, et al. Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol. 2004;137(2):430&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15270863</ArticleId><ArticleId IdType="pmc">1809120</ArticleId></ArticleIdList></Reference><Reference><Citation>Jong KXJ, Mohamed EHM, Ibrahim ZA. Escaping cell death via TRAIL decoy receptors: a systematic review of their roles and expressions in colorectal cancer. Apoptosis Int J Program Cell Death. 2022;27(11&#x2013;12):787&#x2013;99.</Citation></Reference><Reference><Citation>Zhang Y, Tian J, Xiao F, Zheng L, Zhu X, Wu L, et al. B cell-activating factor and its targeted therapy in autoimmune diseases. Cytokine Growth Factor Rev. 2022;64:57&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">34916133</ArticleId></ArticleIdList></Reference><Reference><Citation>Steri M, Orr&#xf9; V, Idda ML, Pitzalis M, Pala M, Zara I, et al. Overexpression of the Cytokine BAFF and Autoimmunity Risk. N Engl J Med. 2017;376(17):1615&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">28445677</ArticleId><ArticleId IdType="pmc">5605835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodde V, Floris M, Beerman I, Munk R, Guha R, Steri M, et al. Evolutionarily Selected Overexpression of the Cytokine BAFF Enhances Mucosal Immune Response Against P. falciparum. Front Immunol. 2020;11:575103.</Citation></Reference><Reference><Citation>Shen X, Zhang R, Nie X, Yang Y, Hua Y, L&#xfc; P. 4&#x2013;1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T. Cancer Biother Radiopharm. 2023 ;38(7):431&#x2013;44.</Citation></Reference><Reference><Citation>Desantis V, Savino FD, Scaringella A, Potenza MA, Nacci C, Frassanito MA, et al. The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. J Clin Med. 2022;11(9):2513.</Citation><ArticleIdList><ArticleId IdType="pubmed">35566637</ArticleId><ArticleId IdType="pmc">9105926</ArticleId></ArticleIdList></Reference><Reference><Citation>1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012 1;491(7422):56&#x2013;65.</Citation></Reference><Reference><Citation>Surapaneni A, Schlosser P, Zhou L, Liu C, Chatterjee N, Arking DE, et al. Identification of 969 protein quantitative trait loci in an African American population with kidney disease attributed to hypertension. Kidney Int. 2022;102(5):1167&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">35870639</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang H, Hui Q, Lynch J, Honerlaw J, Assimes TL, Huang J, et al. Harmonizing Genetic Ancestry and Self-identified Race/Ethnicity in Genome-wide Association Studies. Am J Hum Genet. 2019;105(4):763&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">31564439</ArticleId><ArticleId IdType="pmc">6817526</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang QS, Hasegawa T, Namkoong H, Saiki R, Edahiro R, Sonehara K, et al. Publisher Correction: Statistically and functionally fine-mapped blood eQTLs and pQTLs from 1,405 humans reveal distinct regulation patterns and disease relevance. Nat Genet. 2024;56(10):2281&#x2013;2281.</Citation><ArticleIdList><ArticleId IdType="pubmed">39333769</ArticleId><ArticleId IdType="pmc">11525165</ArticleId></ArticleIdList></Reference><Reference><Citation>LaMonte MJ, Manson JE, Anderson GL, Baker LD, Bea JW, Eaton CB, et al. Contributions of the Women&#x2019;s Health Initiative to Cardiovascular Research: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;80(3):256&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">35835498</ArticleId><ArticleId IdType="pmc">10324098</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol. 1979 ;110(3):281&#x2013;90.</Citation></Reference><Reference><Citation>Carpenter MA, Crow R, Steffes M, Rock W, Heilbraun J, Evans G, et al. Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study. Am J Med Sci. 2004;328(3):131&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">15367870</ArticleId></ArticleIdList></Reference><Reference><Citation>Assarsson E, Lundberg M, Holmquist G, Bj&#xf6;rkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9(4): e95192.</Citation><ArticleIdList><ArticleId IdType="pubmed">24755770</ArticleId><ArticleId IdType="pmc">3995906</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Franceschini N, Surapaneni A, Garrett ME, Tahir UA, Hsu L, et al. Differences in the Circulating Proteome in Individuals with versus without Sickle Cell Trait. Clin J Am Soc Nephrol CJASN. 2023;18(11):1416&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">37533140</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeggini E, Ioannidis JPA. Meta-analysis in genome-wide association studies. Pharmacogenomics. 2009;10(2):191&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">19207020</ArticleId></ArticleIdList></Reference><Reference><Citation>Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinforma Oxf Engl. 2016;32(20):3207&#x2013;9.</Citation></Reference><Reference><Citation>Stegle O, Parts L, Piipari M, Winn J, Durbin R. Using probabilistic estimation of expression residuals (PEER) to obtain increased power and interpretability of gene expression analyses. Nat Protoc. 2012;7(3):500&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22343431</ArticleId><ArticleId IdType="pmc">3398141</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang QQ, Ritchie SC, Brozynska M, Inouye M. Power, false discovery rate and Winner&#x2019;s Curse in eQTL studies. Nucleic Acids Res. 2018;46(22): e133.</Citation><ArticleIdList><ArticleId IdType="pubmed">30189032</ArticleId><ArticleId IdType="pmc">6294523</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science. 2020 11;369(6509):1318&#x2013;30.</Citation></Reference><Reference><Citation>Tong T, Feng Z, Hilton JS, Zhao H. Estimating the Proportion of True Null Hypotheses Using the Pattern of Observed p-values. J Appl Stat. 2013;40(9):1949&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">24078762</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis JR, Fresard L, Knowles DA, Pala M, Bustamante CD, Battle A, et al. An Efficient Multiple-Testing Adjustment for eQTL Studies that Accounts for Linkage Disequilibrium between Variants. Am J Hum Genet. 2016;98(1):216&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">26749306</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinforma Oxf Engl. 2019;35(22):4851&#x2013;3.</Citation></Reference><Reference><Citation>Zhou H, Arapoglou T, Li X, Li Z, Zheng X, Moore J, et al. FAVOR: functional annotation of variants online resource and annotator for variation across the human genome. Nucleic Acids Res. 2023;51(D1):D1300&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">36350676</ArticleId></ArticleIdList></Reference><Reference><Citation>Sollis E, Mosaku A, Abid A, Buniello A, Cerezo M, Gil L, et al. The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource. Nucleic Acids Res. 2023;51(D1):D977&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">36350656</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone J, Holloway E, Adamusiak T, Kapushesky M, Zheng J, Kolesnikov N, et al. Modeling sample variables with an Experimental Factor Ontology. Bioinforma Oxf Engl. 2010;26(8):1112&#x2013;8.</Citation></Reference><Reference><Citation>GWAS Catalog Download [Internet]. [cited 2024 May 9]. Available from: https://www.ebi.ac.uk/gwas/docs/file-downloads</Citation></Reference><Reference><Citation>Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. PLOS Genet. 2014;10(5): e1004383.</Citation><ArticleIdList><ArticleId IdType="pubmed">24830394</ArticleId><ArticleId IdType="pmc">4022491</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Hu E, Cai Y, Xie Z, Luo X, Zhan L, et al. Using clusterProfiler to characterize multiomics data. Nat Protoc. 2024;19(11):3292&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">39019974</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberzon A, Birger C, Thorvaldsd&#xf3;ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database Hallmark Gene Set Collection. Cell Syst. 2015;1(6):417&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">26771021</ArticleId><ArticleId IdType="pmc">4707969</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Klein A, Sang J, Choi J, Brown KM. ezQTL: A Web Platform for Interactive Visualization and Colocalization of QTLs and GWAS Loci. Genomics Proteomics Bioinformatics. 2022;20(3):541&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">35643189</ArticleId><ArticleId IdType="pmc">9801033</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40640957</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1601-5223</ISSN><JournalIssue CitedMedium="Internet"><Volume>162</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Hereditas</Title><ISOAbbreviation>Hereditas</ISOAbbreviation></Journal><ArticleTitle>METTL3 mediates m6A methylation modification of ULBP2 and affects the progression of cervical cancer.</ArticleTitle><Pagination><StartPage>123</StartPage><MedlinePgn>123</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s41065-025-00483-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cervical cancer (CC) is one of the most prevalent malignancies in women, posing a significant challenge globally. However, the precise molecular mechanism regulating CC progression through methyltransferase-like protein 3 (METTL3) and UL16 Binding Protein 2 (ULBP2) remains largely unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Bioinformatic analysis was used to identify the effect of ULBP2 expression in CC tissues. RT-qPCR and western blotting were employed to assess the mRNA and protein expression in CC cells and tissues. Methylthiazolyldiphenyl-tetrazolium bromide (MTT), 5&#x2011;Ethynyl&#x2011;2'&#x2011;deoxyuridine (EdU), wound healing, and transwell assays were utilized to estimate cell viability, proliferation, and metastasis, respectively. Cell apoptosis was detected by flow cytometry. CC cells were treated with different doses of radiotherapy. The m6A level was measured using methylated RNA immunoprecipitation (MeRIP) assay. A xenograft assay was conducted to further verify the roles of ULBP2 in CC.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">ULBP2 was upregulated in CC. Downregulation of ULBP2 restrained the proliferation, metastasis and radiotherapy resistance of CC cells. METTL3 regulated m6A methylation modification of ULBP2. Insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) promoted m6A methylation modification of ULBP2. METTL3 influenced the expression of ULBP2 and impacted the biological function of the CC cells. Silencing ULBP2 reduced the radioresistance of CC in vivo. Radiotherapy altered the gut microbiota in CC patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">METTL3 modulated the m6A methylation of ULBP2, affecting the oncogenic properties and radioresistance of CC cells.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Hongtao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, Second Affiliated Hospital of Xi'an Jiaotong, University, Second Affiliated Hospital of Xi'an Jiaotong University Xinjiang Hospital, No. 157, Siwu Road, Xi'an, Shaanxi, 710004, China. rentao2225153@xjtu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yuting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Radiotherapy Center, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, 830001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Jiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Radiotherapy Center, Shaanxi Provincical People's Hospital, Xi'an, Shaanxi, 710068, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, Second Affiliated Hospital of Xi'an Jiaotong, University, Second Affiliated Hospital of Xi'an Jiaotong University Xinjiang Hospital, No. 157, Siwu Road, Xi'an, Shaanxi, 710004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xiulong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, Second Affiliated Hospital of Xi'an Jiaotong, University, Second Affiliated Hospital of Xi'an Jiaotong University Xinjiang Hospital, No. 157, Siwu Road, Xi'an, Shaanxi, 710004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Jiyuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, Second Affiliated Hospital of Xi'an Jiaotong, University, Second Affiliated Hospital of Xi'an Jiaotong University Xinjiang Hospital, No. 157, Siwu Road, Xi'an, Shaanxi, 710004, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2021SF-138</GrantID><Agency>The General Projects of Shaanxi Province</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hereditas</MedlineTA><NlmUniqueID>0374654</NlmUniqueID><ISSNLinking>0018-0661</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.1.1.-</RegistryNumber><NameOfSubstance UI="D008780">Methyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.62</RegistryNumber><NameOfSubstance UI="C468275">METTL3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>CLE6G00625</RegistryNumber><NameOfSubstance UI="C010223">N-methyladenosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008780" MajorTopicYN="Y">Methyltransferases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008745" MajorTopicYN="N">Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical cancer</Keyword><Keyword MajorTopicYN="N">METTL3</Keyword><Keyword MajorTopicYN="N">N6-methyladenosine</Keyword><Keyword MajorTopicYN="N">Radiotherapy</Keyword><Keyword MajorTopicYN="N">ULBP2</Keyword></KeywordList><CoiStatement>Declarations. Ethical approval and consent to participate: Written informed consents were obtained from all participants and this study was permitted by the Ethics Committee of Second Affiliated Hospital of Xi&#x2019;an Jiaotong University [No. XJTUAE2024-2215]. Consent for publication: Written informed consents were obtained from all participants. Animal studies: Animal studies were performed in compliance with the ARRIVE guidelines and the Basel Declaration. All animals received humane care according to the National Institutes of Health (USA) guidelines. The standards of the Experimental Animal Ethics Committee of Second Affiliated Hospital of Xi&#x2019;an Jiaotong University were adhered to all animal experiments [No. XJTUAE2024-2215]. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>23</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40640957</ArticleId><ArticleId IdType="doi">10.1186/s41065-025-00483-8</ArticleId><ArticleId IdType="pii">10.1186/s41065-025-00483-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arbyn M, Weiderpass E, Bruni L, de Sanjos&#xe9; S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191&#x2013;e203.</Citation></Reference><Reference><Citation>Souandaou Athoumani A, Gul O, Nihal Omur B. Molecular mechanisms of antiproliferative effects of Safranal on cervical cancer: evidence from bioinformatics analysis. Curr Proteomics. 2024;21(5):392&#x2013;405.</Citation></Reference><Reference><Citation>Li Q, Wei X, Zhou ZW, Wang SN, Jin H, Chen KJ, et al. GADD45&#x3b1; sensitizes cervical cancer cells to radiotherapy via increasing cytoplasmic APE1 level. Cell Death Dis. 2018;9(5):524.</Citation></Reference><Reference><Citation>Cosman D, M&#xfc;llberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14(2):123&#x2013;133.</Citation></Reference><Reference><Citation>Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, et al. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother. 2009;58(5):641&#x2013;652.</Citation></Reference><Reference><Citation>Liang HX, Li YH. MiR-873, as a suppressor in cervical cancer, inhibits cells proliferation, invasion and migration via negatively regulating ULBP2. Genes Genomics. 2020;42(4):371&#x2013;382.</Citation></Reference><Reference><Citation>Imamura A, Oike T, Sato H, Yoshimoto Y, Ando K, Ohno T. Comparative analysis of the antitumor immune profiles of paired Radiotherapy-naive and Radiotherapy-treated cervical Cancer tissues. Anticancer Res. 2022;42(7):3341&#x2013;3348.</Citation></Reference><Reference><Citation>Chen XY, Zhang J, Zhu JS. The role of m(6)A RNA methylation in human cancer. Mol Cancer. 2019;18(1):103.</Citation></Reference><Reference><Citation>Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed Pharmacother. 2019;112:108613.</Citation></Reference><Reference><Citation>Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285&#x2013;295.</Citation></Reference><Reference><Citation>Mao Y, Jiang F, Xu XJ, Zhou LB, Jin R, Zhuang LL, Juan CX, Zhou GP. Inhibition of IGF2BP1 attenuates renal injury and inflammation by alleviating m6A modifications and E2F1/MIF pathway. Int J Biol Sci. 2023;19(2):593&#x2013;609.</Citation></Reference><Reference><Citation>Wanna-Udom S, Terashima M, Lyu H, Ishimura A, Takino T, Sakari M, Tsukahara T, Suzuki T. The m6A methyltransferase METTL3 contributes to transforming growth Factor-beta-induced epithelial-mesenchymal transition of lung cancer cells through the regulation of JUNB. Biochem Biophys Res Commun. 2020;524(1):150&#x2013;155.</Citation></Reference><Reference><Citation>Jin Q, Qu H, Quan C. New insights into the regulation of METTL3 and its role in tumors. Cell Communication Signaling: CCS. 2023;21(1):334.</Citation></Reference><Reference><Citation>Guo Y, Bai Y, Wang L, Xu Z, Zhang N, Wang W, Zhao H. METTL3 facilitates the progression of cervical cancer by m6A modification-mediated up-regulation of NEK2. Sci Rep. 2024;14(1):24469.</Citation></Reference><Reference><Citation>Li W, Lu L, Liu B, Qin S. Effects of phycocyanin on pulmonary and gut microbiota in a radiation-induced pulmonary fibrosis model. Biomed Pharmacother. 2020;132:110826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110826</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Hu L, Yang Y, Wang Y, Li Y, Su J, Wang G, Gong S. Saccharomyces boulardii alleviates allergic asthma by restoring gut microbiota and metabolic homeostasis via up-regulation of METTL3 in an m6A-dependent manner. Immunol Lett. 2024;267:106853.</Citation></Reference><Reference><Citation>Chen S, Zhang L, Li M, Zhang Y, Sun M, Wang L, Lin J, Cui Y, Chen Q, Jin C et al. Fusobacterium nucleatum reduces METTL3-mediated m(6)A modification and contributes to colorectal cancer metastasis. Nat Commun. 2022;13(1):1248.</Citation></Reference><Reference><Citation>Liu T, Yang K, Chen J, Qi L, Zhou X, Wang P. Comprehensive Pan-Cancer analysis of KIF18A as a marker for prognosis and immunity. Biomolecules. 2023;13(2).</Citation></Reference><Reference><Citation>Yan L, Xu F, Dai C. Overexpression of COL24A1 in hepatocellular carcinoma predicts poor prognosis: A study based on multiple databases, clinical samples and cell lines. Onco Targets Ther. 2020;13:2819&#x2013;2832.</Citation></Reference><Reference><Citation>Zhai S, Li Y, Yang Y, Lang W, Liu X, Liu K, Qu J, Zhu L. Scinderin is a potential prognostic biomarker and correlated with immunological regulation: from pan-cancer analysis to liver hepatocellular carcinoma. Front Immunol. 2024;15:1361657.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1361657</ArticleId></ArticleIdList></Reference><Reference><Citation>Drapkina OM, Ashniev GA, Zlobovskaya OA, Yafarova AA, Dementeva EV, Kaburova AN, Meshkov IO, Sheptulina AF, Kiselev AR, Kontsevaya AV et al. Diversities in the Gut Microbial Patterns in Patients with Atherosclerotic Cardiovascular Diseases and Certain Heart Failure Phenotypes,. Biomedicines. 2022;10(11).</Citation></Reference><Reference><Citation>Lkhagva E, Chung HJ, Hong J, Tang WHW, Lee SI, Hong ST, Lee S. The regional diversity of gut Microbiome along the GI tract of male C57BL/6 mice. BMC Microbiol. 2021;21(1):44.</Citation></Reference><Reference><Citation>Li Z, Zhang Y, Sui S, Hua Y, Zhao A, Tian X, Wang R, Guo W, Yu W, Zou K et al. Targeting HMGB3/hTERT axis for radioresistance in cervical cancer. J Exp Clin Cancer Res. 2020;39(1):243.</Citation></Reference><Reference><Citation>Zhao PW, Cui JX, Wang XM. Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis. Pharmacogenomics J. 2024;24(2):5.</Citation></Reference><Reference><Citation>Vinje MA, Friedman DA. Exogenous spike-in mouse RNAs for accurate differential gene expression analysis in barley using RT-qPCR. Biol Methods Protoc. 2023;8(1):bpad034.</Citation></Reference><Reference><Citation>Jin C, Li X, Zhang C. Expression of senescence-related CD161 promotes extranodal NK/T cell lymphoma by affecting T cell phenotype and cell cycle. Mol Med. 2024;30(1):230.</Citation></Reference><Reference><Citation>Ward AB, Mir H, Kapur N, Gales DN, Carriere PP, Singh S. Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways. World J Surg Oncol. 2018;16(1):108.</Citation></Reference><Reference><Citation>Zheng Y, Zeng Y, Qiu R, Liu R, Huang W, Hou Y, Wang S, Leng S, Feng D, Yang Y et al. The homeotic protein SIX3 suppresses carcinogenesis and metastasis through recruiting the LSD1/NuRD(MTA3) complex. Theranostics. 2018;8(4):972&#x2013;989.</Citation></Reference><Reference><Citation>Deng YR, Wu QZ, Zhang W, Jiang HP, Xu CQ, Chen SC, Fan J, Guo SQ, Chen XJ. Apoptotic cell-derived extracellular vesicles-MTA1 confer radioresistance in cervical cancer by inducing cellular dormancy. J Transl Med. 2025;23(1):328.</Citation></Reference><Reference><Citation>Ouyang P, Li K, Xu W, Chen C, Shi Y, Tian Y, Gong J, Bao Z. METTL3 recruiting M2-type immunosuppressed macrophages by targeting m6A-SNAIL-CXCL2 axis to promote colorectal cancer pulmonary metastasis. J Exp Clin Cancer Res. 2024;43(1):111.</Citation></Reference><Reference><Citation>Huang S, Zhang J, Qiao Y, Pathak JL, Zou R, Piao Z, Xie S, Liang J, Ouyang K. CHRDL1 inhibits OSCC metastasis via MAPK signaling-mediated Inhibition of MED29. Mol Med. 2024;30(1):187.</Citation></Reference><Reference><Citation>Sun Y, Shen W, Hu S, Lyu Q, Wang Q, Wei T, Zhu W, Zhang J. METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy. J Exp Clin Cancer Res. 2023;42(1):65.</Citation></Reference><Reference><Citation>Cui Y, Wen Y, Lv C, Zhao D, Yang Y, Qiu H, Wang C. Decreased RNA&#x2013;binding protein IGF2BP2 downregulates NT5DC2, which suppresses cell proliferation, and induces cell cycle arrest and apoptosis in diffuse large B&#x2013;cell lymphoma cells by regulating the p53 signaling pathway. Mol Med Rep. 2022;26(3).</Citation></Reference><Reference><Citation>Yu M, Ni M, Xu F, Liu C, Chen L, Li J, Xia S, Diao Y, Chen J, Zhu J et al. NSUN6-mediated 5-methylcytosine modification of NDRG1 mRNA promotes radioresistance in cervical cancer. Mol Cancer. 2024;23(1):139.</Citation></Reference><Reference><Citation>Hou Y, Zhang X, Yao H, Hou L, Zhang Q, Tao E, Zhu X, Jiang S, Ren Y, Hong X et al. METTL14 modulates Glycolysis to inhibit colorectal tumorigenesis in p53-wild-type cells. EMBO Rep. 2023;24(4):e56325.</Citation></Reference><Reference><Citation>Hu J, Lin H, Wang C, Su Q, Cao B. METTL14&#x2013;mediated RNA methylation in digestive system tumors. Int J Mol Med. 2023;52(3).</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2023.5289</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, Zhang H, Guo X, Zhu Z, Cai H, Kong X. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer. J Hematol Oncol. 2018;11(1):88.</Citation></Reference><Reference><Citation>Zhang S, Wang Q, Zhou C, Chen K, Chang H, Xiao W, Gao Y. Colorectal cancer, radiotherapy and gut microbiota. Chin J Cancer Res. 2019;31(1):212&#x2013;222.</Citation></Reference><Reference><Citation>Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2007.05.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezache L, Paniccia B, Nyinawabera A, Nuovo GJ. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol. 2015;28(12):1594&#x2013;1602.</Citation></Reference><Reference><Citation>Kasamon YL, de Claro RA, Wang Y, Shen YL, Farrell AT, Pazdur R. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical hodgkin lymphoma. Oncologist. 2017;22(5):585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2017-0004</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun R, Chen C, Deng X, Wang F, Song S, Cai Q, Wang J, Zhang T, Shi M, Ke Q et al. IL-11 mediates the radioresistance of cervical Cancer cells via the PI3K/Akt signaling pathway. J Cancer. 2021;12(15):4638&#x2013;4647.</Citation></Reference><Reference><Citation>Tang Y, Chen K, Song B, Ma J, Wu X, Xu Q, Wei Z, Su J, Liu G, Rong R et al. m6A-Atlas: a comprehensive knowledgebase for unraveling the N6-methyladenosine (m6A) epitranscriptome. Nucleic Acids Res. 2021;49(D1):D134&#x2013;d143.</Citation></Reference><Reference><Citation>Li X, Xiong W, Long X, Dai X, Peng Y, Xu Y, Zhang Z, Zhang L, Liu Y. Inhibition of METTL3/m6A/miR126 promotes the migration and invasion of endometrial stromal cells in endometriosis&#x2020;. Biol Reprod. 2021;105(5):1221&#x2013;1233.</Citation></Reference><Reference><Citation>Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m(6)A modification. Cell Stem Cell. 2018;22(2):191&#x2013;205.e199.</Citation></Reference><Reference><Citation>Degrauwe N, Suv&#xe0; ML, Janiszewska M, Riggi N, Stamenkovic I. IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer. Genes Dev. 2016;30(22):2459&#x2013;2474.</Citation></Reference><Reference><Citation>Wu Z, Shi Y, Lu M, Song M, Yu Z, Wang J, Wang S, Ren J, Yang YG, Liu GH et al. METTL3 counteracts premature aging via m6A-dependent stabilization of MIS12 mRNA. Nucleic Acids Res. 2020;48(19):11083&#x2013;11096.</Citation></Reference><Reference><Citation>Sims TT, Colbert LE, Zheng J, Delgado Medrano AY, Hoffman KL, Ramondetta L, Jazaeri A, Jhingran A, Schmeler KM, Daniel CR et al. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecol Oncol. 2019;155(2):237&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ygyno.2019.09.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Agus A, Cl&#xe9;ment K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut. 2021;70(6):1174&#x2013;1182.</Citation></Reference><Reference><Citation>Fong W, Li Q, Yu J. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. Oncogene. 2020;39(26):4925&#x2013;4943.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40640953</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-6362</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Arthritis research &amp; therapy</Title><ISOAbbreviation>Arthritis Res Ther</ISOAbbreviation></Journal><ArticleTitle>Roles of JAK-STAT signaling and granulocyte-macrophage colony-stimulating factor in the development of osteitis and bone microstructure changes in rheumatoid arthritis.</ArticleTitle><Pagination><StartPage>143</StartPage><MedlinePgn>143</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13075-025-03597-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Osteitis on magnetic resonance imaging (MRI) and bone microstructure changes (BMC) on high-resolution peripheral quantitative computed tomography (CT) are the earliest signs of arthritis, preceding the development of bone erosion on X-ray in rheumatoid arthritis (RA). Recently, a Janus kinase (JAK) inhibitor, baricitinib, reportedly suppresses these early changes. This study aimed to elucidate the underlying molecular mechanism of osteitis and BMC using an animal model of RA and human samples.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Osteitis and BMCs were assessed via MRI and micro-CT, respectively, in zymosan-treated SKG mice. Bone marrow (BM) cells were analysed via flow cytometry. JAK&#x2012;signal transducer and activator of transcription (STAT) cytokine expression was measured via performing quantitative PCR. Zymosan-treated SKG mice received baricitinib, anti-granulocyte&#x2012;macrophage colony-stimulating factor (GM-CSF) antibodies, or recombinant GM-CSF (r-GM-CSF). r-GM-CSF was also used in an in vitro osteoclast differentiation assay. Osteoclast differentiation was also investigated with human monocytes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Osteitis and BMCs occurred prior to arthritis in SKG mice. Granulocyte&#x2012;macrophage-lineage cells and osteoclast precursor cells (OCPs) expanded in the inflammatory BM. Receptor activator of nuclear factor kappa-B ligand-positive osteoclasts were observed at BMC sites. The expression of GM-CSF, a JAK&#x2012;STAT cytokine, was upregulated in osteitic BM. Both baricitinib and anti-GM-CSF antibodies suppressed osteitis and BMCs, whereas r-GM-CSF exacerbated these changes. In vitro addition of r-GM-CSF to osteoclast differentiation assay markedly increased the number and size of osteoclasts, especially when added in the late phase of osteoclast differentiation both in mice and humans.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">GM-CSF drives osteitis and BMCs by increasing granulocyte&#x2012;macrophage-lineage cells and OCPs and promoting osteoclast differentiation. Targeting GM-CSF is a potential therapeutic strategy to prevent early radiographic changes in RA.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Tsuneyasu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Bristol Myers Squibb Building, Konoe cho-Yoshida, Sakyo-ku, Kyoto, 606-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murotani</LastName><ForeName>Yoshiki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopeadic Surgery, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murata</LastName><ForeName>Koichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Orthopeadic Surgery, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Advanced Medicine for Rheumatic Diseases, Kyoto University, Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606- 8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imai</LastName><ForeName>Hirohiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Informatics, Graduate School of Informatics, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakayama</LastName><ForeName>Yoichi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsushima</LastName><ForeName>Masao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirakashi</LastName><ForeName>Mirei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakashima</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Ryu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murakami</LastName><ForeName>Kosaku</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Bristol Myers Squibb Building, Konoe cho-Yoshida, Sakyo-ku, Kyoto, 606-8501, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshifuji</LastName><ForeName>Hajime</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morinobu</LastName><ForeName>Akio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Motomu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan. motomu.hashimoto@omu.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Not applicable</GrantID><Agency>Eli Lilly Japan K.K</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arthritis Res Ther</MedlineTA><NlmUniqueID>101154438</NlmUniqueID><ISSNLinking>1478-6354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>83869-56-1</RegistryNumber><NameOfSubstance UI="D016178">Granulocyte-Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.2</RegistryNumber><NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050791">STAT Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>ISP4442I3Y</RegistryNumber><NameOfSubstance UI="C000596027">baricitinib</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001384">Azetidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016178" MajorTopicYN="Y">Granulocyte-Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010000" MajorTopicYN="Y">Osteitis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053612" MajorTopicYN="Y">Janus Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050791" MajorTopicYN="Y">STAT Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001842" MajorTopicYN="Y">Bone and Bones</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010010" MajorTopicYN="N">Osteoclasts</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055114" MajorTopicYN="N">X-Ray Microtomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001384" MajorTopicYN="N">Azetidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declarations. Ethics approval and consent to participate: All animal experiments were approved by the Kyoto University Animal Ethics Committee (approval number Medkyo 16106&#x2013;23104). All experiments using human samples were approved by the ethics committee of Kyoto University Graduate School and Faculty of Medicine (approval number R1166-3). Consent for publication: Not applicable. Competing interests: TY has received speaker fees from AbbVie GK, Asahi Kasei Pharma Corp., and Eli Lilly Japan K.K. MH has received research grants from AbbVie GK, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Bristol-Myers Squibb., Eisai Co. Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Novartis Pharma Co. Ltd., Taisho Toyama Co. Ltd., and Towa Pharma Co. Ltd., and speaker fees from Bristol-Myers Squibb., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., and Mitsubishi Tanabe Pharma Corp. Ltd. YM has received honoraria from Asahi Kasei Pharma Corp. RW has received a grant from AbbVie GK, and has received honoraria from AbbVie GK, Chugai Pharmaceutical Co. Ltd., Asahi Kasei Pharma Corp., GlaxoSmithKline, Eli Lilly Japan K.K., and UCB Japan. KM has received honoraria from Chugai Pharmaceutical Co., Ltd., and Asahi Kasei Pharma Corp. AM has received research grants from AbbVie GK, Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp. Ltd., and Eisai Co. Ltd., and has received honoraria from AbbVie GK, Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Eisai Co. Ltd., Pfizer Inc., Bristol-Myers Squibb., Mitsubishi Tanabe Pharma Corp., Astellas Pharma Inc., and Gilead Sciences Japan.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>23</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40640953</ArticleId><ArticleId IdType="doi">10.1186/s13075-025-03597-6</ArticleId><ArticleId IdType="pii">10.1186/s13075-025-03597-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gravallese EM, Firestein GS. Rheumatoid Arthritis - Common origins, divergent mechanisms. N Engl J Med. 2023;388:529&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">36780677</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison BJ, Hutchinson CE, Adams J, Bruce IN, Herrick AL. Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Ann Rheum Dis. 2002;61:1007&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">12379525</ArticleId><ArticleId IdType="pmc">1753932</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;ler-Y&#xfc;ksel M, Allaart CF, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, van Groenendael JHLM, Mall&#xe9;e C, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis. 2009;68:330&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18375540</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;ler-Y&#xfc;ksel M, Bijsterbosch J, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Hulsmans HMJ, de Beus WM, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. Ann Rheum Dis. 2008;67:823&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17644545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetland ML, Ejbjerg B, H&#xf8;rslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). Ann Rheum Dis. 2009;68:384&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">18388160</ArticleId></ArticleIdList></Reference><Reference><Citation>Krabben A, Stomp W, van Nies Ja, Huizinga B, van der Heijde TWJ, Bloem D. MRI-detected subclinical joint inflammation is associated with radiographic progression. Ann Rheum Dis. 2014;73:2034&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25074691</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon D, Kleyer A, Cong DB, Hueber A, Bang H, Ramming A, et al. Microstructural bone changes are associated with Broad-Spectrum autoimmunity and predict the onset of rheumatoid arthritis. Arthritis Rheumatol. 2022;74:418&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">32067367</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. 2014;73:854&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">23520034</ArticleId></ArticleIdList></Reference><Reference><Citation>van Steenbergen HW, Mangnus L, Reijnierse M, Huizinga TWJ, van der Helm-van Mil AHM. Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. Ann Rheum Dis. 2016;75:1824&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">26613769</ArticleId></ArticleIdList></Reference><Reference><Citation>Smiljanovic B, Radzikowska A, Kuca-Warnawin E, Kurowska W, Gr&#xfc;n JR, Stuhlm&#xfc;ller B, et al. Monocyte alterations in rheumatoid arthritis are dominated by preterm release from bone marrow and prominent triggering in the joint. Ann Rheum Dis. 2018;77:300&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29191820</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita T, Shimaoka Y, Kashiwagi N, Hashimoto H, Kawamura S, Lee SB, et al. Enhanced expression of CD14 antigen on myeloid lineage cells derived from the bone marrow of patients with severe rheumatoid arthritis. J Rheumatol. 1997;24:465&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9058650</ArticleId></ArticleIdList></Reference><Reference><Citation>Haavardsholm EA, B&#xf8;yesen P, &#xd8;stergaard M, Schildvold A, Kvien TK. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis. 2008;67:794&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">17981915</ArticleId></ArticleIdList></Reference><Reference><Citation>McQueen FM, Benton N, Perry D, Crabbe J, Robinson E, Yeoman S, et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum. 2003;48:1814&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847674</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon D, Minopoulou I, Kemenes S, Bayat S, Tascilar K, Mutlu MY, et al. Baricitinib improves bone properties and biomechanics in patients with rheumatoid arthritis: results of the prospective interventional BARE BONE trial. Arthritis Rheumatol. 2023;75:1923&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">37229650</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterfy C, DiCarlo J, Emery P, Genovese MC, Keystone EC, Taylor PC, et al. MRI and dose selection in a phase II trial of baricitinib with conventional synthetic Disease-modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 2019;46:887&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">30647190</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam S, Simon N, Steffen U, Andes FT, Scholtysek C, M&#xfc;ller DIH, et al. JAK Inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function. Sci Transl Med. 2020;12:eaay4447.</Citation><ArticleIdList><ArticleId IdType="pubmed">32051226</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan-Komito D, Swann JW, Demetriou P, Cohen ES, Horwood NJ, Sansom SN, et al. GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis. Nat Commun. 2020;11:155.</Citation><ArticleIdList><ArticleId IdType="pubmed">31919358</ArticleId><ArticleId IdType="pmc">6952438</ArticleId></ArticleIdList></Reference><Reference><Citation>Charles JF, Hsu LY, Niemi EC, Weiss A, Aliprantis AO, Nakamura MC. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J Clin Invest. 2012;122:4592&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pubmed">23114597</ArticleId><ArticleId IdType="pmc">3533532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lari R, Fleetwood AJ, Kitchener PD, Cook AD, Pavasovic D, Hertzog PJ, et al. Macrophage lineage phenotypes and osteoclastogenesis&#x2013;complexity in the control by GM-CSF and TGF-beta. Bone. 2007;40(2):323&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">17055352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodge JM, Kirkland MA, Aitken CJ, Waugh CM, Myers DE, Lopez CM, et al. Osteoclastic potential of human CFU-GM: biphasic effect of GM-CSF. J Bone Min Res. 2004;19:190&#x2013;9.</Citation></Reference><Reference><Citation>Kurihara N, Suda T, Miura Y, Nakauchi H, Kodama H, Hiura K, et al. Generation of osteoclasts from isolated hematopoietic progenitor cells. Blood. 1989;74:1295&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">2669999</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi N, Udagawa N, Akatsu T, Tanaka H, Shionome M, Suda T. Role of colony-stimulating factors in osteoclast development. J Bone Min Res. 1991;6:977&#x2013;85.</Citation></Reference><Reference><Citation>Horwood NJ, Udagawa N, Elliott J, Grail D, Okamura H, Kurimoto M, et al. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest. 1998;101:595&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">9449693</ArticleId><ArticleId IdType="pmc">508603</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MS, Day CJ, Morrison NA. MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem. 2005;280:16163&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15722361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki K, Sakaue S, Terao C, Luo Y, Sonehara K, Yamaguchi K, et al. Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis. Nat Genet. 2022;54:1640&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">36333501</ArticleId><ArticleId IdType="pmc">10165422</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazal S, Weissbrod O, Hormozdiari F, Dey KK, Nasser J, Jagadeesh KA, et al. Combining SNP-to-gene linking strategies to identify disease genes and assess disease omnigenicity. Nat Genet. 2022;54:827&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">35668300</ArticleId><ArticleId IdType="pmc">9894581</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai M, Akiyama M, Takahashi A, Matoba N, Momozawa Y, Ikeda M, et al. Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. Nat Genet. 2018;50:390&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">29403010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HM, Sugino H, Aoki C, Shimaoka Y, Suzuki R, Ochi K, et al. Abnormal networks of immune response-related molecules in bone marrow cells from patients with rheumatoid arthritis as revealed by DNA microarray analysis. Arthritis Res Ther. 2011;13:R89.</Citation><ArticleIdList><ArticleId IdType="pubmed">21679443</ArticleId><ArticleId IdType="pmc">3218904</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, et al. PID: the pathway interaction database. Nucleic Acids Res. 2009;37:D674&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">18832364</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu N, Takayanagi H. Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions. Nat Rev Rheumatol. 2022;18:415&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">35705856</ArticleId></ArticleIdList></Reference><Reference><Citation>McQueen FM. Bone marrow edema and osteitis in rheumatoid arthritis: the imaging perspective. Arthritis Res Ther. 2012;14:224.</Citation><ArticleIdList><ArticleId IdType="pubmed">23043770</ArticleId><ArticleId IdType="pmc">3580509</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Boj E, N&#xf6;bauer-Huhmann I, Hanslik-Schnabel B, Dorotka R, Wanivenhaus AH, Kainberger F, et al. Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum. 2007;56:1118&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">17393390</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalbeth N, Smith T, Gray S, Doyle A, Antill P, Lobo M, et al. Cellular characterisation of magnetic resonance imaging bone oedema in rheumatoid arthritis; implications for pathogenesis of erosive disease. Ann Rheum Dis. 2009;68:279&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">18765428</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiasa M, Abe M, Nakano A, Oda A, Amou H, Kido S, et al. GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE). Blood. 2009;114:4517&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">19762488</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher B, Tugues S, Greter M. GM-CSF: from growth factor to central mediator of tissue inflammation. Immunity. 2016;45:963&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">27851925</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelfinger F, De Feo D, Becher B. GM-CSF: master regulator of the T cell-phagocyte interface during inflammation. Semin Immunol. 2021;54:101518.</Citation><ArticleIdList><ArticleId IdType="pubmed">34763973</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao B, Ivashkiv LB. Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors. Arthritis Res Therapy. 2011;28:13:234.</Citation></Reference><Reference><Citation>Mbalaviele G, Novack DV, Schett G, Teitelbaum SL. Inflammatory osteolysis: a conspiracy against bone. J Clin Invest. 2017;127:2030&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28569732</ArticleId><ArticleId IdType="pmc">5451216</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd8;stergaard M, Jacobsson LTH, Schaufelberger C, Hansen MS, Bijlsma JWJ, Dudek A, et al. MRI assessment of early response to certolizumab Pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16. Ann Rheum Dis. 2015;74:1156&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">25512675</ArticleId></ArticleIdList></Reference><Reference><Citation>Conaghan PG, Peterfy C, Olech E, Kaine J, Ridley D, Dicarlo J, et al. The effects of Tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy. Ann Rheum Dis. 2014;73:810&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24525910</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton JA. GM-CSF in inflammation and autoimmunity. Trends Immunol. 2002;23:403&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12133803</ArticleId></ArticleIdList></Reference><Reference><Citation>Caux C, Saeland S, Favre C, Duvert V, Mannoni P, Banchereau J. Tumor necrosis factor-alpha strongly potentiates interleukin-3 and granulocyte-macrophage colony-stimulating factor-induced proliferation of human CD34&#x2009;+&#x2009;hematopoietic progenitor cells. Blood. 1990;75:2292&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1693526</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor PC, Weinblatt ME, McInnes IB, Atsumi T, Strand V, Takeuchi T, et al. Anti-GM-CSF Otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3). Ann Rheum Dis. 2023;82:1527&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">37696589</ArticleId></ArticleIdList></Reference><Reference><Citation>Komagamine M, Komatsu N, Ling R, Okamoto K, Tianshu S, Matsuda K, et al. Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic bone loss. Inflamm Regen. 2023;43:44.</Citation><ArticleIdList><ArticleId IdType="pubmed">37726797</ArticleId><ArticleId IdType="pmc">10507845</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Luo A, Xuan W, Qi L, Wu Q, Gan K, et al. The bone marrow edema links to an osteoclastic environment and precedes synovitis during the development of collagen induced arthritis. Front Immunol. 2019;10:884.</Citation><ArticleIdList><ArticleId IdType="pubmed">31068949</ArticleId><ArticleId IdType="pmc">6491763</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40640948</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-9966</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of experimental &amp; clinical cancer research : CR</Title><ISOAbbreviation>J Exp Clin Cancer Res</ISOAbbreviation></Journal><ArticleTitle>PHGDH drives 5-FU chemoresistance in colorectal cancer through the Hedgehog signaling.</ArticleTitle><Pagination><StartPage>198</StartPage><MedlinePgn>198</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13046-025-03447-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Phosphoglycerate dehydrogenase (PHGDH) is the rate-limiting enzyme in the de novo Serine synthesis pathway (SSP), a highly regulated pathway overexpressed in several tumors. Specifically, PHGDH expression is dynamically regulated during different stages of tumor progression, promoting cancer aggressiveness. Previously, we demonstrated that high Serine (Ser) availability, obtained by increased exogenous uptake or increased PHGDH expression, supports 5-Fluorouracil (5-FU) resistance in colorectal cancer (CRC). Beyond its metabolic role in sustaining Ser biosynthesis, different "non-enzymatic roles" for PHGDH have recently been identified. The present study aims to investigate non-enzymatic mechanisms through which PHGDH regulates 5-FU response in CRC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Overexpression and gene silencing approaches have been used to modulate PHGDH expression in human CRC cell lines to investigate the role of this enzyme in 5-FU cellular response. Identified mechanisms have been validated in selected 5-FU resistant cell lines, CRC patients-derived tumor tissue samples, and patients-derived 3D organoids. Transcriptomic analysis was performed on wild-type and PHGDH-silenced cell lines, allowing the identification of pathways responsible for PHGDH-mediated 5-FU resistance. The relevance of identified genes was validated in vitro and in vivo in a CRC xenograft model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">PHGDH expression is highly variable among CRC tissues and patient-derived 3D organoids. A retrospective analysis of CRC patients highlighted a correlation between PHGDH expression and therapy response. Coherently, the modulation of PHGDH expression by gene silencing/overexpression affects 5-FU sensitivity in CRC cell lines. Transcriptomic analysis on CRC cell lines stably silenced for PHGDH evidenced down regulation in Hedgehog (HH) pathway. Accordingly, in vitro and in vivo studies demonstrated that the combined treatment of 5-FU and HH pathway inhibitors strongly hinders CRC cell survival and tumor growth in CRC xenograft models.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">PHGDH sustains 5-FU resistance in CRC by mediating the upregulation of the HH signaling; targeting the here identified PHGDH-HH axis increases 5-FU susceptibility in different CRC models suggesting the 5-FU/HH-inhibitors combinatorial therapeutic strategy as a valid approach to counteract drug resistance in CRC.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Mancini</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lori</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mattei</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Clinical Pharmacology and Oncology Unit, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iozzo</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desideri</LastName><ForeName>Dayana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cianchi</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortuna</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passagnoli</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Massi</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Health Sciences, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ugolini</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Health Sciences, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Messerini</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Health Sciences, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piscuoglio</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pezone</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magherini</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biagioni</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lottini</LastName><ForeName>Tiziano</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zambardino</LastName><ForeName>Demetra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truglio</LastName><ForeName>Giuseppina Ivana</ForeName><Initials>GI</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petricci</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Information Engineering, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arcangeli</LastName><ForeName>Annarosa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maresca</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, University of Naples "Federico II", Naples, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Information Engineering, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Core Research Laboratory, ISPRO, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stecca</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Core Research Laboratory, ISPRO, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pranzini</LastName><ForeName>Erica</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy. erica.pranzini@unifi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taddei</LastName><ForeName>Maria Letizia</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. marialetizia.taddei@unifi.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IG27094</GrantID><Agency>Associazione Italiana per la Ricerca sul Cancro</Agency><Country/></Grant><Grant><GrantID>ECS00000017-CUP B83C22003920001</GrantID><Agency>Tuscany Health Ecosystem</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Exp Clin Cancer Res</MedlineTA><NlmUniqueID>8308647</NlmUniqueID><ISSNLinking>0392-9078</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.1.1.95</RegistryNumber><NameOfSubstance UI="D050543">Phosphoglycerate Dehydrogenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053823">Hedgehog Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="Y">Fluorouracil</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050543" MajorTopicYN="Y">Phosphoglycerate Dehydrogenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019008" MajorTopicYN="Y">Drug Resistance, Neoplasm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053823" MajorTopicYN="Y">Hedgehog Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000964" MajorTopicYN="N">Antimetabolites, Antineoplastic</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">5-Fluorouracil</Keyword><Keyword MajorTopicYN="N">Chemo-resistance</Keyword><Keyword MajorTopicYN="N">Colorectal cancer</Keyword><Keyword MajorTopicYN="N">Hedgehog signaling</Keyword><Keyword MajorTopicYN="N">Phosphoglycerate dehydrogenase</Keyword><Keyword MajorTopicYN="N">Serine</Keyword><Keyword MajorTopicYN="N">Stemness</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Ethical approval for this study was obtained from &#x201c;Comitato Etico Regionale per la Sperimentazione Clinica della Regione Toscana; sez: Area Vasta Centro"-Protocol: 24030_BIO. All animal experiments were approved by the Italian ethical committee of Animal Welfare Office of Italian Work Ministry and conformed to the legal mandates and Italian guidelines for the care and maintenance of laboratory animals (authorization number: 981/2024-PR). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>23</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40640948</ArticleId><ArticleId IdType="doi">10.1186/s13046-025-03447-y</ArticleId><ArticleId IdType="pii">10.1186/s13046-025-03447-y</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Yang M, Vousden KH. Serine and one-carbon metabolism in cancer. Nat Rev Cancer. 2016;16(10):650&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">27634448</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CM, Hwang Y, Kim M, Park YC, Kim H, Fang S. PHGDH: a novel therapeutic target in cancer. Exp Mol Med. 2024;56(7):1513&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">38945960</ArticleId><ArticleId IdType="pmc">11297271</ArticleId></ArticleIdList></Reference><Reference><Citation>Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476(7360):346&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">21760589</ArticleId><ArticleId IdType="pmc">3353325</ArticleId></ArticleIdList></Reference><Reference><Citation>Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011;43(9):869&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">21804546</ArticleId><ArticleId IdType="pmc">3677549</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Z, Feng C, Lu Y, Lin Y, Dong C. PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer. Gene. 2018;642:43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">29128633</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaneton B, Hillmann P, Zheng L, Martin ACL, Maddocks ODK, Chokkathukalam A, et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature. 2012;491(7424):458&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">23064226</ArticleId><ArticleId IdType="pmc">3894725</ArticleId></ArticleIdList></Reference><Reference><Citation>Tajan M, Hennequart M, Cheung EC, Zani F, Hock AK, Legrave N, et al. Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy. Nat Commun. 2021;12(1):366.</Citation><ArticleIdList><ArticleId IdType="pubmed">33446657</ArticleId><ArticleId IdType="pmc">7809039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma X, Li B, Liu J, Fu Y, Luo Y. Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E. J Exp Clin Cancer Res. 2019;38(1):66.</Citation><ArticleIdList><ArticleId IdType="pubmed">30744688</ArticleId><ArticleId IdType="pmc">6371491</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu Y, Hao Y, Feng J, Liu H, Li ST, Jiang Z, et al. Non-canonical phosphoglycerate dehydrogenase activity promotes liver cancer growth via mitochondrial translation and respiratory metabolism. EMBO J. 2022;41(23): e111550.</Citation><ArticleIdList><ArticleId IdType="pubmed">36314841</ArticleId><ArticleId IdType="pmc">9713714</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Guo S, Li Q, Yang L, Xia Z, Zhang L, et al. Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1. J Neurooncol. 2013;111(3):245&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">23229761</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H, Yu H, Zhou H, Zhu W, Wang X. Elevated Nuclear PHGDH Synergistically Functions with cMyc to Reshape the Immune Microenvironment of Liver Cancer. Adv Sci (Weinh). 2023;10(17): e2205818.</Citation><ArticleIdList><ArticleId IdType="pubmed">37078828</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C, Zheng K, Jiang K, Zhao Q, Sha N, Wang W, et al. The alternative activity of nuclear PHGDH contributes to tumour growth under nutrient stress. Nat Metab. 2021;3(10):1357&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">34663976</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Li T, Liu D, Liu Y, Long Z, Wu Y, et al. Interaction of PHGDH with IGF2BP1 facilitates m6A-dependent stabilization of TCF7L2 mRNA to confer multidrug resistance in gastric cancer. Oncogene. 2025;44(25):2064&#x2013;77.</Citation></Reference><Reference><Citation>Kumar A, Gautam V, Sandhu A, Rawat K, Sharma A, Saha L. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. World J Gastrointest Surg. 2023;15(4):495&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">37206081</ArticleId><ArticleId IdType="pmc">10190721</ArticleId></ArticleIdList></Reference><Reference><Citation>Azwar S, Seow HF, Abdullah M, Faisal Jabar M, Mohtarrudin N. Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment. Biology (Basel). 2021;10(9):854.</Citation></Reference><Reference><Citation>Gon&#xe7;alves AC, Richiardone E, Jorge J, Pol&#xf3;nia B, Xavier CPR, Salaroglio IC, et al. Impact of cancer metabolism on therapy resistance - Clinical implications. Drug Resist Updat. 2021;59: 100797.</Citation><ArticleIdList><ArticleId IdType="pubmed">34955385</ArticleId></ArticleIdList></Reference><Reference><Citation>Pranzini E, Pardella E, Muccillo L, Leo A, Nesi I, Santi A, et al. SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis. Cell Rep. 2022;40(7): 111233.</Citation><ArticleIdList><ArticleId IdType="pubmed">35977477</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J. Hedgehog signaling mechanism and role in cancer. Semin Cancer Biol. 2022;85:107&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">33836254</ArticleId></ArticleIdList></Reference><Reference><Citation>Denise C, Paoli P, Calvani M, Taddei ML, Giannoni E, Kopetz S, et al. 5-Fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits. Oncotarget. 2015;6(39):41706&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26527315</ArticleId><ArticleId IdType="pmc">4747183</ArticleId></ArticleIdList></Reference><Reference><Citation>Maresca L, Crivaro E, Migliorini F, Anichini G, Giammona A, Pepe S, et al. Targeting GLI1 and GLI2 with small molecule inhibitors to suppress GLI-dependent transcription and tumor growth. Pharmacol Res. 2023;195: 106858.</Citation><ArticleIdList><ArticleId IdType="pubmed">37473878</ArticleId></ArticleIdList></Reference><Reference><Citation>Lori G, Pastore M, Navari N, Piombanti B, Booijink R, Rovida E, et al. Altered fatty acid metabolism rewires cholangiocarcinoma stemness features. JHEP Rep. 2024;6(10): 101182.</Citation><ArticleIdList><ArticleId IdType="pubmed">39430578</ArticleId><ArticleId IdType="pmc">11486925</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett&#x2019;s epithelium. Gastroenterology. 2011;141(5):1762&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21889923</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii M, Shimokawa M, Date S, Takano A, Matano M, Nanki K, et al. A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during Tumorigenesis. Cell Stem Cell. 2016;18(6):827&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">27212702</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinucci M, Ercan C, Taha-Mehlitz S, Fourie L, Panebianco F, Bianco G, et al. Standardizing Patient-Derived Organoid Generation Workflow to Avoid Microbial Contamination From Colorectal Cancer Tissues. Front Oncol. 2021;11: 781833.</Citation><ArticleIdList><ArticleId IdType="pubmed">35083141</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrelli C, Roberts M, Eletto D, Hussherr MD, Fazilaty H, Valenta T, et al. In vivo interaction screening reveals liver-derived constraints to metastasis. Nature. 2024;632(8024):411&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">39048831</ArticleId><ArticleId IdType="pmc">11306111</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha-Mehlitz S, Bianco G, Coto-Llerena M, Kancherla V, Bantug GR, Gallon J, et al. Adenylosuccinate lyase is oncogenic in colorectal cancer by causing mitochondrial dysfunction and independent activation of NRF2 and mTOR-MYC-axis. Theranostics. 2021;11(9):4011&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">33754045</ArticleId><ArticleId IdType="pmc">7977451</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia XQ, Zhang S, Zhu HJ, Wang W, Zhu JH, Wang XD, et al. Increased Expression of PHGDH and Prognostic Significance in Colorectal Cancer. Transl Oncol. 2016;9(3):191&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27267836</ArticleId><ArticleId IdType="pmc">4907894</ArticleId></ArticleIdList></Reference><Reference><Citation>Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28263959</ArticleId><ArticleId IdType="pmc">5600148</ArticleId></ArticleIdList></Reference><Reference><Citation>Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res. 2015;4:1521.</Citation><ArticleIdList><ArticleId IdType="pubmed">26925227</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.</Citation><ArticleIdList><ArticleId IdType="pubmed">25516281</ArticleId><ArticleId IdType="pmc">4302049</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanover JA, Krause MW, Love DC. Bittersweet memories: linking metabolism to epigenetics through O-GlcNAcylation. Nat Rev Mol Cell Biol. 2012;13(5):312&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">22522719</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi M, Altea-Manzano P, Demicco M, Doglioni G, Bornes L, Fukano M, et al. PHGDH heterogeneity potentiates cancer cell dissemination and metastasis. Nature. 2022;605(7911):747&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">35585241</ArticleId><ArticleId IdType="pmc">9888363</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimi N, Afshinpour M, Fakhr SS, Kalkhoran PG, Shadman-Manesh V, Adelian S, et al. Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance. Crit Rev Oncol Hematol. 2023;182: 103920.</Citation><ArticleIdList><ArticleId IdType="pubmed">36702423</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. World J Gastroenterol. 2023;29(9):1395&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">36998426</ArticleId><ArticleId IdType="pmc">10044855</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Tang L, Huang H, Yu Q, Hu B, Wang G, et al. Phosphoglycerate dehydrogenase activates PKM2 to phosphorylate histone H3T11 and attenuate cellular senescence. Nat Commun. 2023;14(1):1323.</Citation><ArticleIdList><ArticleId IdType="pubmed">36899022</ArticleId><ArticleId IdType="pmc">10006232</ArticleId></ArticleIdList></Reference><Reference><Citation>Annibali D, Fendt SM. Nuclear PHGDH protects cancer cells from nutrient stress. Nat Metab. 2021;3(10):1284&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">34663972</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Y, Tu R, Liu H, Qing G. Regulation of cancer cell metabolism: oncogenic MYC in the driver&#x2019;s seat. Signal Transduct Target Ther. 2020;5(1):124.</Citation><ArticleIdList><ArticleId IdType="pubmed">32651356</ArticleId><ArticleId IdType="pmc">7351732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HL, Wang P, Lu MZ, Zhang SD, Zheng L. c-Myc maintains the self-renewal and chemoresistance properties of colon cancer stem cells. Oncol Lett. 2019;17(5):4487&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">30944638</ArticleId><ArticleId IdType="pmc">6444394</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing J, Wu Z, Wang J, Luo G, Lin H, Fan Y, et al. Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies. Signal Transduct Target Ther. 2023;8(1):315.</Citation><ArticleIdList><ArticleId IdType="pubmed">37596267</ArticleId><ArticleId IdType="pmc">10439210</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang FT, Zhuan-Sun YX, Zhuang YY, Wei SL, Tang J, Chen WB, et al. Inhibition of hedgehog signaling depresses self-renewal of pancreatic cancer stem cells and reverses chemoresistance. Int J Oncol. 2012;41(5):1707&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">22923052</ArticleId></ArticleIdList></Reference><Reference><Citation>He M, Fu Y, Yan Y, Xiao Q, Wu H, Yao W, et al. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients. Clin Sci (Lond). 2015;129(9):809&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">26201092</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, DU F, Zhao Q, Jin J, Ma X, Li H. Acquisition of 5-fluorouracil resistance induces epithelial-mesenchymal transitions through the Hedgehog signaling pathway in HCT-8 colon cancer cells. Oncol Lett. 2015;9(6):2675&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26137127</ArticleId><ArticleId IdType="pmc">4473303</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong G, Zhu X, Chen XR, Chen H, Chong W. Mechanisms and therapeutic potential of the hedgehog signaling pathway in cancer. Cell Death Discov. 2025;11(1):40.</Citation><ArticleIdList><ArticleId IdType="pubmed">39900571</ArticleId><ArticleId IdType="pmc">11791101</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Song R, Gu D, Zhang X, Yu B, Liu B, et al. The role of GLI1 for 5-Fu resistance in colorectal cancer. Cell Biosci. 2017;7:17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28413604</ArticleId><ArticleId IdType="pmc">5390459</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B, Gu D, Zhang X, Liu B, Xie J. The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer. J Genet Genomics. 2017;44(8):375&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">28847472</ArticleId><ArticleId IdType="pmc">5604254</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonnissen A, Isebaert S, Haustermans K. Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened. Oncotarget. 2015;6(16):13899&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pubmed">26053182</ArticleId><ArticleId IdType="pmc">4546439</ArticleId></ArticleIdList></Reference><Reference><Citation>Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.</Citation></Reference><Reference><Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">21376230</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattaini KR, Sullivan MR, Vander Heiden MG. The importance of serine metabolism in cancer. J Cell Biol. 2016;214(3):249&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">27458133</ArticleId><ArticleId IdType="pmc">4970329</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan MR, Mattaini KR, Dennstedt EA, Nguyen AA, Sivanand S, Reilly MF, et al. Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting. Cell Metab. 2019;29(6):1410-21.e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">30905671</ArticleId><ArticleId IdType="pmc">6551255</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Fu J, Du J, Xu W. The Role of D-3-Phosphoglycerate Dehydrogenase in Cancer. Int J Biol Sci. 2020;16(9):1495&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">32226297</ArticleId><ArticleId IdType="pmc">7097917</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei L, Lee D, Law CT, Zhang MS, Shen J, Chin DW, et al. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat Commun. 2019;10(1):4681.</Citation><ArticleIdList><ArticleId IdType="pubmed">31615983</ArticleId><ArticleId IdType="pmc">6794322</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong JK, Lei HM, Liang Q, Tang YB, Zhou Y, Wang Y, et al. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase. Theranostics. 2018;8(7):1808&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">29556358</ArticleId><ArticleId IdType="pmc">5858502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaal EA, Wu W, Jansen G, Zweegman S, Cloos J, Berkers CR. Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer Metab. 2017;5:7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28855983</ArticleId><ArticleId IdType="pmc">5575874</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross KC, Andrews AJ, Marion CD, Yen TJ, Bhattacharjee V. Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non-Small Cell Lung Cancer Cells. Mol Cancer Ther. 2017;16(8):1596&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">28500236</ArticleId><ArticleId IdType="pmc">5544579</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Bai W. Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin. Cancer Chemother Pharmacol. 2016;78(3):655&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27473325</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu B, Gu D, Zhang X, Li J, Liu B, Xie J. GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer. Oncotarget. 2017;8(16):27412&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">28404967</ArticleId><ArticleId IdType="pmc">5432345</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H, Tian Y, Yu X. Targeting Smoothened Sensitizes Gastric Cancer to Chemotherapy in Experimental Models. Med Sci Monit. 2017;23:1493&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">28350784</ArticleId><ArticleId IdType="pmc">5381338</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M, Gong A, Yang H, George SK, Jiao Z, Huang H, et al. Sonic hedgehog-glioma associated oncogene homolog 1 signaling enhances drug resistance in CD44(+)/Musashi-1(+) gastric cancer stem cells. Cancer Lett. 2015;369(1):124&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">26276718</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Ma J, Avery JT, Sambandam V, Nguyen TH, Xu B, et al. GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAF. Front Oncol. 2020;10:241.</Citation><ArticleIdList><ArticleId IdType="pubmed">32185127</ArticleId><ArticleId IdType="pmc">7058788</ArticleId></ArticleIdList></Reference><Reference><Citation>Usui T, Sakurai M, Umata K, Elbadawy M, Ohama T, Yamawaki H, et al. Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture. Int J Mol Sci . 2018;19(4):1098. https://doi.org/10.3390/ijms19041098 .</Citation></Reference><Reference><Citation>Duan X, Chen Y, Zhang K, Chen W, Zhao J, Dai X, et al. PHGDH promotes esophageal squamous cell carcinoma progression via Wnt/&#x3b2;-catenin pathway. Cell Signal. 2023;109: 110736.</Citation><ArticleIdList><ArticleId IdType="pubmed">37263462</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon JW, Gallant M, Lamm ML, Iannaccone S, Vieux KF, Proytcheva M, et al. Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma. Mol Cancer Res. 2013;11(6):604&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">23525267</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40640944</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2049-3002</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>10</Day></PubDate></JournalIssue><Title>Cancer &amp; metabolism</Title><ISOAbbreviation>Cancer Metab</ISOAbbreviation></Journal><ArticleTitle>Fatty acid synthase-derived lipid stores support breast cancer metastasis.</ArticleTitle><Pagination><StartPage>35</StartPage><MedlinePgn>35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40170-025-00404-3</ELocationID><Abstract><AbstractText>Lipid accumulation is associated with breast cancer metastasis. However, the mechanisms underlying how breast cancer cells increase lipid stores and their functional role in disease progression remain incompletely understood. Herein we quantified changes in lipid metabolism and characterized cytoplasmic lipid droplets in metastatic versus non-metastatic breast cancer cells. <sup>14</sup>C-labeled palmitate was used to determine differences in fatty acid (FA) uptake and oxidation. Despite similar levels of palmitate uptake, metastatic cells increase lipid accumulation and oxidation of endogenous FAs compared to non-metastatic cells. Isotope tracing also demonstrated that metastatic cells support increased de novo lipogenesis by converting higher levels of glutamine and glucose into the FA precursor, citrate. Consistent with this, metastatic cells displayed increased levels of fatty acid synthase (FASN) and de novo lipogenesis. Genetic depletion or pharmacologic inhibition of FASN reduced cell migration, survival in anoikis assays, and in vivo metastasis. Finally, global proteomic analysis indicated that proteins involved in proteasome function, mitotic cell cycle, and intracellular protein transport were reduced following FASN inhibition of metastatic cells. Overall, these studies demonstrate that breast cancer metastases accumulate FAs by increasingde novo lipogenesis, storing TAG as cytoplasmic lipid droplets, and catabolizing these stores to drive several FAO-dependent steps in metastasis.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andolino</LastName><ForeName>Chaylen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Nutrition Science, Purdue University, West Lafayette, IN, 47907, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotul</LastName><ForeName>Eylem Kulkoyluoglu</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xianyu</LastName><ForeName>Zilin</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa, Iowa City, IA, 52242, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhat</LastName><ForeName>Divya</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa, Iowa City, IA, 52242, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayers</LastName><ForeName>Mitchell</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buhman</LastName><ForeName>Kimberly K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Department of Nutrition Science, Purdue University, West Lafayette, IN, 47907, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hursting</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Nutrition, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wendt</LastName><ForeName>Michael K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa, Iowa City, IA, 52242, USA. mkwendt@uiowa.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA. mkwendt@uiowa.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teegarden</LastName><ForeName>Dorothy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Nutrition Science, Purdue University, West Lafayette, IN, 47907, USA. dteegard@purdue.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN, USA. dteegard@purdue.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01CA232589</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01CA232589</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01CA232589</GrantID><Acronym>GF</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>#TR000006</GrantID><Agency>NIH/NCRR</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cancer Metab</MedlineTA><NlmUniqueID>101607582</NlmUniqueID><ISSNLinking>2049-3002</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast cancer</Keyword><Keyword MajorTopicYN="N">FASN</Keyword><Keyword MajorTopicYN="N">Fatty acid synthase</Keyword><Keyword MajorTopicYN="N">Fatty acids</Keyword><Keyword MajorTopicYN="N">Lipid droplet</Keyword><Keyword MajorTopicYN="N">Lipid metabolism</Keyword><Keyword MajorTopicYN="N">Lipid storage</Keyword><Keyword MajorTopicYN="N">Mass spectrometry</Keyword><Keyword MajorTopicYN="N">Metastasis</Keyword><Keyword MajorTopicYN="N">TNBC</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>11</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>23</Hour><Minute>54</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40640944</ArticleId><ArticleId IdType="doi">10.1186/s40170-025-00404-3</ArticleId><ArticleId IdType="pii">10.1186/s40170-025-00404-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">36633525</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully OJ, Bay BH, Yip G, Yu Y. Breast cancer metastasis. Cancer Genomics Proteomics. 2012;9(5):311&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22990110</ArticleId></ArticleIdList></Reference><Reference><Citation>Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">22000009</ArticleId><ArticleId IdType="pmc">3261217</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">35022204</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergers G, Fendt SM. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021;21(3):162&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">33462499</ArticleId><ArticleId IdType="pmc">8733955</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.</Citation><ArticleIdList><ArticleId IdType="pubmed">27386546</ArticleId><ArticleId IdType="pmc">4928883</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">18177721</ArticleId></ArticleIdList></Reference><Reference><Citation>Warburg O. The metabolism of carcinoma cells. J Cancer Res. 1925;9(1):148&#x2013;63.</Citation></Reference><Reference><Citation>Ayre WB, Ayre JE. Cancer; evolutionary reversion in cell metabolism. Am J Obstet Gynecol. 1947;54(6):970&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">20272302</ArticleId></ArticleIdList></Reference><Reference><Citation>Young VR. Energy metabolism and requirements in the cancer patient. Cancer Res. 1977;37(7 Pt 2):2336&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">324612</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218(1):e20201606.</Citation><ArticleIdList><ArticleId IdType="pubmed">33601415</ArticleId></ArticleIdList></Reference><Reference><Citation>Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;25(5):e189.</Citation></Reference><Reference><Citation>Baumann J, Sevinsky C, Conklin DS. Lipid biology of breast cancer. Biochim Biophys Acta. 2013;1831(10):1509&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">23562840</ArticleId><ArticleId IdType="pmc">3926128</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Zhang H. Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cell Mol Life Sci. 2016;73(2):377&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">26499846</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastaniotis AJ, Autio KJ, Ker&#xe4;t&#xe4;r JM, Monteuuis G, M&#xe4;kel&#xe4; AM, Nair RR, et al. Mitochondrial fatty acid synthesis, fatty acids and mitochondrial physiology. Biochim Biophys Acta Mol Cell Biol Lipids. 2017;1862(1):39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">27553474</ArticleId></ArticleIdList></Reference><Reference><Citation>Bl&#xfc;cher C, Stadler SC. Obesity and breast cancer: current insights on the role of fatty acids and lipid metabolism in promoting breast cancer growth and progression. Front Endocrinol (Lausanne). 2017;8:293.</Citation><ArticleIdList><ArticleId IdType="pubmed">29163362</ArticleId></ArticleIdList></Reference><Reference><Citation>Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res. 1997;3(11):2115&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9815604</ArticleId></ArticleIdList></Reference><Reference><Citation>Monaco ME, Osborne CK, Lippman ME. Insulin stimulation of fatty acid synthesis in human breast cancer cells. J Natl Cancer Inst. 1977;58(6):1591&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">559098</ArticleId></ArticleIdList></Reference><Reference><Citation>Monaco ME. Fatty acid metabolism in breast cancer subtypes. Oncotarget. 2017;8(17):29487&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">28412757</ArticleId><ArticleId IdType="pmc">5438746</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Peng Q, Wang YW, Qiu J, Zhu J, Ma R. Prognostic and clinicopathological significance of fatty acid synthase in breast cancer: A systematic review and meta-analysis. Front Oncol. 2023;12(13):1153076.</Citation></Reference><Reference><Citation>Menendez JA, Lupu R. Fatty acid synthase: a druggable driver of breast cancer brain metastasis. Expert Opin Ther Targets. 2022;26(5):427&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">35545806</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinlaw WB, Baures PW, Lupien LE, Davis WL, Kuemmerle NB. Fatty Acids and Breast Cancer: Make Them on Site or Have Them Delivered. J Cell Physiol. 2016;231(10):2128&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">26844415</ArticleId><ArticleId IdType="pmc">4912394</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher ER, Gregorio R, Kim WS, Redmond C. Lipid in invasive cancer of the breast. Am J Clin Pathol. 1977;68(5):558&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">920651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos CV, Taylor HB. Lipid-rich carcinoma of the breast. A clinicopathologic analysis of 13 examples. Cancer. 1974;33(3):812&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">4815583</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson KE, Bachawal SV, Tian L, Willmann JK. Multiparametric spectroscopic photoacoustic imaging of breast cancer development in a transgenic mouse model. Theranostics. 2014;4(11):1062&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">25285161</ArticleId><ArticleId IdType="pmc">4173758</ArticleId></ArticleIdList></Reference><Reference><Citation>Petan T, Jarc E, Jusovi&#x107; M. Lipid droplets in cancer: guardians of fat in a stressful world. Molecules. 2018;23(8):E1941.</Citation></Reference><Reference><Citation>Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM, et al. Fatty acid uptake and lipid storage induced by HIF-1&#x3b1; contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep. 2014;9(1):349&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">25263561</ArticleId></ArticleIdList></Reference><Reference><Citation>Koizume S, Miyagi Y. Lipid droplets: a key cellular organelle associated with cancer cell survival under normoxia and hypoxia. Int J Mol Sci. 2016;17(9):E1430.</Citation></Reference><Reference><Citation>Gruslova A, McClellan B, Balinda HU, Viswanadhapalli S, Alers V, Sareddy GR, et al. FASN inhibition as a potential treatment for endocrine-resistant breast cancer. Breast Cancer Res Treat. 2021;187(2):375&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">33893909</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CI, Chan HW, Shen CY, Chuang HY. Targeting fatty acid synthase to halt tumor progression and enhance radiosensitivity in breast cancer cells. J Med Biol Eng. 2024;44(6):903&#x2013;13.</Citation></Reference><Reference><Citation>Wang F, Ma S, Chen P, Han Y, Liu Z, Wang X, et al. Imaging the metabolic reprograming of fatty acid synthesis pathway enables new diagnostic and therapeutic opportunity for breast cancer. Cancer Cell Int. 2023;23(1):83.</Citation><ArticleIdList><ArticleId IdType="pubmed">37120513</ArticleId><ArticleId IdType="pmc">10149015</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, et al. Fatty acid synthesis is required for breast cancer brain metastasis. Nat Cancer. 2021;2(4):414&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">34179825</ArticleId><ArticleId IdType="pmc">8223728</ArticleId></ArticleIdList></Reference><Reference><Citation>Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, et al. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat. 2001;65(2):101&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">11261825</ArticleId></ArticleIdList></Reference><Reference><Citation>Strickland LB, Dawson PJ, Santner SJ, Miller FR. Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers. Breast Cancer Res Treat. 2000;64(3):235&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">11200773</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilmanski T, Buhman K, Donkin SS, Burgess JR, Teegarden D. 1&#x3b1;,25-dihydroxyvitamin D inhibits de novo fatty acid synthesis and lipid accumulation in metastatic breast cancer cells through down-regulation of pyruvate carboxylase. J Nutr Biochem. 2017;1(40):194&#x2013;200.</Citation></Reference><Reference><Citation>Sheeley MP, Kiesel VA, Andolino C, Lanman NA, Donkin SS, Hursting SD, et al. 1&#x3b1;,25-dihydroxyvitamin D reduction of MCF10A-ras cell viability in extracellular matrix detached conditions is dependent on regulation of pyruvate carboxylase. J Nutr Biochem. 2022;109:109116.</Citation><ArticleIdList><ArticleId IdType="pubmed">35934270</ArticleId><ArticleId IdType="pmc">9719603</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendt MK, Williams WK, Pascuzzi PE, Balanis NG, Schiemann BJ, Carlin CR, et al. The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6. Neoplasia. 2015;17(1):124&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">25622905</ArticleId><ArticleId IdType="pmc">4309683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali R, Brown W, Purdy SC, Davisson VJ, Wendt MK. Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand. Cell Death Dis. 2018;9(10):976.</Citation><ArticleIdList><ArticleId IdType="pubmed">30250119</ArticleId><ArticleId IdType="pmc">6155319</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendt MK, Schiemann WP. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-&#x3b2; signaling and metastasis. Breast Cancer Res. 2009;11(5):R68.</Citation><ArticleIdList><ArticleId IdType="pubmed">19740433</ArticleId><ArticleId IdType="pmc">2790843</ArticleId></ArticleIdList></Reference><Reference><Citation>Zembroski AS, Andolino C, Buhman KK, Teegarden D. Proteomic characterization of cytoplasmic lipid droplets in human metastatic breast cancer cells. Front Oncol. 2021;1(11):576326.</Citation></Reference><Reference><Citation>Siddiqui SMK, Chang E, Li J, Burlage C, Zou M, Buhman KK, et al. Dietary intervention with vitamin d, calcium and whey protein reduced fat mass and increased lean mass in rats. Nutr Res. 2008;28(11):783&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">19083488</ArticleId><ArticleId IdType="pmc">2644487</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier F, Brunner AD, Frank M, Ha A, Bludau I, Voytik E, et al. diaPASEF: parallel accumulation&#x2013;serial fragmentation combined with data-independent acquisition. Nat Methods. 2020;17(12):1229&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">33257825</ArticleId></ArticleIdList></Reference><Reference><Citation>Demichev V, Messner CB, Vernardis SI, Lilley KS, Ralser M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat Methods. 2020;17(1):41&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">31768060</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2&#x2212;&#x394;&#x394;CT method. Methods. 2001;25(4):402&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinde A, Wilmanski T, Chen H, Teegarden D, Wendt MK. Pyruvate carboxylase supports the pulmonary tropism of metastatic breast cancer. Breast Cancer Res. 2018;20(1):76.</Citation><ArticleIdList><ArticleId IdType="pubmed">30005601</ArticleId><ArticleId IdType="pmc">6045837</ArticleId></ArticleIdList></Reference><Reference><Citation>Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">13671378</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis LG, Casey TM, Sobreira TJP, Cooper BR, Ferreira CR. Step-by-step approach to build Multiple Reaction Monitoring (MRM) profiling instrument acquisition methods for class-based lipid exploratory analysis by mass spectrometry. J Biomol Tech. 2023;34(2):3fc1f5fe.1972c438.</Citation><ArticleIdList><ArticleId IdType="pubmed">37435389</ArticleId><ArticleId IdType="pmc">10332339</ArticleId></ArticleIdList></Reference><Reference><Citation>Molenaar MR, Jeucken A, Wassenaar TA, van de Lest CHA, Brouwers JF, Helms JB. LION/web: a web-based ontology enrichment tool for lipidomic data analysis. Gigascience. 2019;8(6):giz061.</Citation><ArticleIdList><ArticleId IdType="pubmed">31141612</ArticleId><ArticleId IdType="pmc">6541037</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendt MK, Taylor MA, Schiemann BJ, Sossey-Alaoui K, Schiemann WP. Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor &#x3b2;1 signaling in metastatic breast cancers. Breast Cancer Res. 2014;16(2):R24.</Citation><ArticleIdList><ArticleId IdType="pubmed">24618085</ArticleId><ArticleId IdType="pmc">4053226</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T, Zhou L, Li H, Tian Y, Li J, Dong L, et al. Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma. Oncol Lett. 2017;14(5):5934&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">29113229</ArticleId><ArticleId IdType="pmc">5661422</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya D, Scim&#xe8; A. Metabolic Regulation of Epithelial to Mesenchymal Transition: Implications for Endocrine Cancer. Frontiers in Endocrinology]. 2019;10. Available from: https://www.frontiersin.org/articles/10.3389/fendo.2019.00773 . Cited 2022 Oct 28.</Citation></Reference><Reference><Citation>Giudetti AM, De Domenico S, Ragusa A, Lunetti P, Gaballo A, Franck J, et al. A specific lipid metabolic profile is associated with the epithelial mesenchymal transition program. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864(3):344&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">30578966</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Dong L, Wei D, Wang X, Zhang S, Li H. Fatty acid synthase mediates the epithelial-mesenchymal transition of breast cancer cells. Int J Biol Sci. 2014;10(2):171&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">24520215</ArticleId><ArticleId IdType="pmc">3920172</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-Mart&#xed;nez R, Cruz-Gil S, G&#xf3;mez de Cedr&#xf3;n M, &#xc1;lvarez-Fern&#xe1;ndez M, Vargas T, Molina S, et al. A link between lipid metabolism and epithelial-mesenchymal transition provides a target for colon cancer therapy. Oncotarget. 2015;6(36):38719&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">26451612</ArticleId><ArticleId IdType="pmc">4770732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao XL, Lv YF, Li DF, Bai FH, Gong J, Pan GQ, et al. TC2N inhibits distant metastasis and stemness of breast cancer via blocking fatty acid synthesis. J Transl Med. 2024;22(1):6.</Citation><ArticleIdList><ArticleId IdType="pubmed">38167440</ArticleId><ArticleId IdType="pmc">10763294</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Ma S, Chen P, Han Y, Liu Z, Wang X, et al. Imaging the metabolic reprograming of fatty acid synthesis pathway enables new diagnostic and therapeutic opportunity for breast cancer. Cancer Cell Int. 2023;23(1):83.</Citation><ArticleIdList><ArticleId IdType="pubmed">37120513</ArticleId><ArticleId IdType="pmc">10149015</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder B, Vander Steen T, Espinoza I, Venkatapoorna CMK, Hu Z, Silva FM, et al. Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. Cell Death Dis. 2021;12(11):977.</Citation><ArticleIdList><ArticleId IdType="pubmed">34675185</ArticleId><ArticleId IdType="pmc">8531299</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>